WO2005033094A2 - Verfahren zur herstellung von 3-methylamino-1-(thien-2-yl)-propan-1-ol - Google Patents
Verfahren zur herstellung von 3-methylamino-1-(thien-2-yl)-propan-1-ol Download PDFInfo
- Publication number
- WO2005033094A2 WO2005033094A2 PCT/EP2004/010939 EP2004010939W WO2005033094A2 WO 2005033094 A2 WO2005033094 A2 WO 2005033094A2 EP 2004010939 W EP2004010939 W EP 2004010939W WO 2005033094 A2 WO2005033094 A2 WO 2005033094A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dehydrogenase
- thien
- propan
- reduction
- nucleic acid
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 92
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 14
- YEJVVFOJMOHFRL-UHFFFAOYSA-N 3-(methylamino)-1-thiophen-2-ylpropan-1-ol Chemical compound CNCCC(O)C1=CC=CS1 YEJVVFOJMOHFRL-UHFFFAOYSA-N 0.000 title claims abstract description 11
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 77
- 230000014509 gene expression Effects 0.000 claims abstract description 31
- 239000013598 vector Substances 0.000 claims abstract description 31
- 101710088194 Dehydrogenase Proteins 0.000 claims description 60
- 230000009467 reduction Effects 0.000 claims description 53
- 238000006243 chemical reaction Methods 0.000 claims description 51
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 39
- 230000008569 process Effects 0.000 claims description 36
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 28
- 239000002904 solvent Substances 0.000 claims description 28
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 25
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 24
- 239000003638 chemical reducing agent Substances 0.000 claims description 22
- 108010021809 Alcohol dehydrogenase Proteins 0.000 claims description 21
- 150000004678 hydrides Chemical class 0.000 claims description 21
- 102000007698 Alcohol dehydrogenase Human genes 0.000 claims description 20
- 241000894006 Bacteria Species 0.000 claims description 20
- 239000003054 catalyst Substances 0.000 claims description 20
- MSLOAFIOTOHDIE-UHFFFAOYSA-N 3-chloro-1-thiophen-2-ylpropan-1-one Chemical compound ClCCC(=O)C1=CC=CS1 MSLOAFIOTOHDIE-UHFFFAOYSA-N 0.000 claims description 19
- 239000002253 acid Substances 0.000 claims description 19
- -1 acrylic acid halide Chemical class 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 19
- 230000001105 regulatory effect Effects 0.000 claims description 18
- 108020005199 Dehydrogenases Proteins 0.000 claims description 17
- 240000001929 Lactobacillus brevis Species 0.000 claims description 16
- 229910052751 metal Inorganic materials 0.000 claims description 16
- 239000002184 metal Substances 0.000 claims description 16
- 244000005700 microbiome Species 0.000 claims description 16
- 235000013957 Lactobacillus brevis Nutrition 0.000 claims description 15
- 230000002829 reductive effect Effects 0.000 claims description 15
- 239000002841 Lewis acid Substances 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 13
- 150000004820 halides Chemical class 0.000 claims description 13
- 229930192474 thiophene Natural products 0.000 claims description 13
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 12
- 241000222292 [Candida] magnoliae Species 0.000 claims description 12
- 150000007517 lewis acids Chemical class 0.000 claims description 12
- 230000036961 partial effect Effects 0.000 claims description 12
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims description 10
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 10
- YEJVVFOJMOHFRL-ZETCQYMHSA-N (1s)-3-(methylamino)-1-thiophen-2-ylpropan-1-ol Chemical compound CNCC[C@H](O)C1=CC=CS1 YEJVVFOJMOHFRL-ZETCQYMHSA-N 0.000 claims description 9
- 239000007795 chemical reaction product Substances 0.000 claims description 9
- YISRPYKYTBBHBK-LURJTMIESA-N (1s)-3-chloro-1-thiophen-2-ylpropan-1-ol Chemical compound ClCC[C@H](O)C1=CC=CS1 YISRPYKYTBBHBK-LURJTMIESA-N 0.000 claims description 8
- 108091026890 Coding region Proteins 0.000 claims description 8
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 238000002955 isolation Methods 0.000 claims description 8
- 241000235648 Pichia Species 0.000 claims description 7
- 241000186660 Lactobacillus Species 0.000 claims description 6
- 125000000539 amino acid group Chemical group 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 229910000039 hydrogen halide Inorganic materials 0.000 claims description 6
- 239000012433 hydrogen halide Substances 0.000 claims description 6
- 229910052723 transition metal Inorganic materials 0.000 claims description 6
- 150000003624 transition metals Chemical class 0.000 claims description 6
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 5
- 241000159512 Geotrichum Species 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 241000589516 Pseudomonas Species 0.000 claims description 5
- 229940039696 lactobacillus Drugs 0.000 claims description 5
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- 241000589158 Agrobacterium Species 0.000 claims description 4
- 241001453380 Burkholderia Species 0.000 claims description 4
- 244000168141 Geotrichum candidum Species 0.000 claims description 4
- 150000008282 halocarbons Chemical class 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 235000017388 Geotrichum candidum Nutrition 0.000 claims description 3
- 241000316848 Rhodococcus <scale insect> Species 0.000 claims description 3
- 241000235070 Saccharomyces Species 0.000 claims description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 abstract description 26
- 108090000790 Enzymes Proteins 0.000 abstract description 26
- 230000002255 enzymatic effect Effects 0.000 abstract description 4
- 238000006911 enzymatic reaction Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 47
- 238000006722 reduction reaction Methods 0.000 description 45
- 108020004707 nucleic acids Proteins 0.000 description 39
- 102000039446 nucleic acids Human genes 0.000 description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
- 108090000765 processed proteins & peptides Proteins 0.000 description 30
- 239000000243 solution Substances 0.000 description 30
- 102000004196 processed proteins & peptides Human genes 0.000 description 29
- 229920001184 polypeptide Polymers 0.000 description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- 229940088598 enzyme Drugs 0.000 description 24
- 108020004414 DNA Proteins 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 23
- 239000007987 MES buffer Substances 0.000 description 21
- 150000002576 ketones Chemical class 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 18
- 239000002609 medium Substances 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 229910052736 halogen Inorganic materials 0.000 description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 239000008103 glucose Substances 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 14
- 238000009396 hybridization Methods 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 108091034117 Oligonucleotide Proteins 0.000 description 12
- 239000000499 gel Substances 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 12
- 150000002367 halogens Chemical class 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 239000013615 primer Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 238000012163 sequencing technique Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 238000010367 cloning Methods 0.000 description 10
- 239000002773 nucleotide Substances 0.000 description 10
- 239000008188 pellet Substances 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 239000012614 Q-Sepharose Substances 0.000 description 9
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
- 239000008272 agar Substances 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 9
- 229960002866 duloxetine Drugs 0.000 description 9
- 238000000855 fermentation Methods 0.000 description 9
- 230000004151 fermentation Effects 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 8
- 238000005917 acylation reaction Methods 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- 230000033228 biological regulation Effects 0.000 description 8
- BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- YISRPYKYTBBHBK-UHFFFAOYSA-N 3-chloro-1-thiophen-2-ylpropan-1-ol Chemical compound ClCCC(O)C1=CC=CS1 YISRPYKYTBBHBK-UHFFFAOYSA-N 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 7
- 239000012505 Superdex™ Substances 0.000 description 7
- 229910052782 aluminium Inorganic materials 0.000 description 7
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 7
- 239000005515 coenzyme Substances 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000002808 molecular sieve Substances 0.000 description 7
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 239000007984 Tris EDTA buffer Substances 0.000 description 6
- 230000010933 acylation Effects 0.000 description 6
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 6
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000000287 crude extract Substances 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 238000004255 ion exchange chromatography Methods 0.000 description 6
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 238000010369 molecular cloning Methods 0.000 description 6
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 6
- 239000012279 sodium borohydride Substances 0.000 description 6
- 229910000033 sodium borohydride Inorganic materials 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- INUNLMUAPJVRME-UHFFFAOYSA-N 3-chloropropanoyl chloride Chemical compound ClCCC(Cl)=O INUNLMUAPJVRME-UHFFFAOYSA-N 0.000 description 5
- 108700010070 Codon Usage Proteins 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 5
- 150000001350 alkyl halides Chemical class 0.000 description 5
- 229910000085 borane Inorganic materials 0.000 description 5
- 229940041514 candida albicans extract Drugs 0.000 description 5
- 239000012876 carrier material Substances 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- YVWGMAFXEJHFRO-UHFFFAOYSA-N halopropane Chemical compound FC(F)C(F)(F)CBr YVWGMAFXEJHFRO-UHFFFAOYSA-N 0.000 description 5
- 229950000188 halopropane Drugs 0.000 description 5
- 238000002744 homologous recombination Methods 0.000 description 5
- 230000006801 homologous recombination Effects 0.000 description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 5
- 125000000468 ketone group Chemical group 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000012138 yeast extract Substances 0.000 description 5
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 4
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 4
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 4
- 238000005863 Friedel-Crafts acylation reaction Methods 0.000 description 4
- 229930091371 Fructose Natural products 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- 239000005715 Fructose Substances 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 239000000010 aprotic solvent Substances 0.000 description 4
- 229910052796 boron Inorganic materials 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- VURFVHCLMJOLKN-UHFFFAOYSA-N diphosphane Chemical compound PP VURFVHCLMJOLKN-UHFFFAOYSA-N 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 238000001742 protein purification Methods 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 229910052707 ruthenium Inorganic materials 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- OCJBOOLMMGQPQU-UHFFFAOYSA-N 1,4-dichlorobenzene Chemical compound ClC1=CC=C(Cl)C=C1 OCJBOOLMMGQPQU-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 3
- FEJUGLKDZJDVFY-UHFFFAOYSA-N 9-borabicyclo(3.3.1)nonane Chemical compound C1CCC2CCCC1B2 FEJUGLKDZJDVFY-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000002028 Biomass Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 108010093096 Immobilized Enzymes Proteins 0.000 description 3
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 3
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 3
- 102000016943 Muramidase Human genes 0.000 description 3
- 108010014251 Muramidase Proteins 0.000 description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000012431 aqueous reaction media Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000009876 asymmetric hydrogenation reaction Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 239000013611 chromosomal DNA Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940117389 dichlorobenzene Drugs 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004325 lysozyme Substances 0.000 description 3
- 229960000274 lysozyme Drugs 0.000 description 3
- 235000010335 lysozyme Nutrition 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002987 primer (paints) Substances 0.000 description 3
- 239000012429 reaction media Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 2
- QPFMBZIOSGYJDE-UHFFFAOYSA-N 1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)C(Cl)Cl QPFMBZIOSGYJDE-UHFFFAOYSA-N 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- PCXJASANFWPUMO-UHFFFAOYSA-N 1-(methylamino)propan-1-ol Chemical compound CCC(O)NC PCXJASANFWPUMO-UHFFFAOYSA-N 0.000 description 2
- RZWHKKIXMPLQEM-UHFFFAOYSA-N 1-chloropropan-1-ol Chemical compound CCC(O)Cl RZWHKKIXMPLQEM-UHFFFAOYSA-N 0.000 description 2
- KZCXXSWHDLPICN-UHFFFAOYSA-N 1-thiophen-2-ylprop-1-en-1-ol Chemical compound CC=C(O)C1=CC=CS1 KZCXXSWHDLPICN-UHFFFAOYSA-N 0.000 description 2
- WYJOVVXUZNRJQY-UHFFFAOYSA-N 2-Acetylthiophene Chemical compound CC(=O)C1=CC=CS1 WYJOVVXUZNRJQY-UHFFFAOYSA-N 0.000 description 2
- VDJKJPMLWJWQIH-UHFFFAOYSA-M 5-ethylphenazin-5-ium;ethyl sulfate Chemical compound CCOS([O-])(=O)=O.C1=CC=C2[N+](CC)=C(C=CC=C3)C3=NC2=C1 VDJKJPMLWJWQIH-UHFFFAOYSA-M 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 241001135756 Alphaproteobacteria Species 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241001135755 Betaproteobacteria Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 241000588921 Enterobacteriaceae Species 0.000 description 2
- 241000192128 Gammaproteobacteria Species 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 241000194036 Lactococcus Species 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000007993 MOPS buffer Substances 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 241000947836 Pseudomonadaceae Species 0.000 description 2
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 2
- 241001633102 Rhizobiaceae Species 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 150000001414 amino alcohols Chemical class 0.000 description 2
- 125000003277 amino group Chemical class 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical class [H]OC(*)=O 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000002742 combinatorial mutagenesis Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 150000004292 cyclic ethers Chemical class 0.000 description 2
- WJTCGQSWYFHTAC-UHFFFAOYSA-N cyclooctane Chemical compound C1CCCCCCC1 WJTCGQSWYFHTAC-UHFFFAOYSA-N 0.000 description 2
- 239000004914 cyclooctane Substances 0.000 description 2
- 238000006356 dehydrogenation reaction Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 150000004985 diamines Chemical class 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 2
- 239000002815 homogeneous catalyst Substances 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000011968 lewis acid catalyst Substances 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000006872 mrs medium Substances 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 150000007524 organic acids Chemical group 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 239000003586 protic polar solvent Substances 0.000 description 2
- 210000001938 protoplast Anatomy 0.000 description 2
- 239000012217 radiopharmaceutical Substances 0.000 description 2
- 229940121896 radiopharmaceutical Drugs 0.000 description 2
- 230000002799 radiopharmaceutical effect Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000011946 reduction process Methods 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 150000003333 secondary alcohols Chemical class 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- NUMQCACRALPSHD-UHFFFAOYSA-N tert-butyl ethyl ether Chemical compound CCOC(C)(C)C NUMQCACRALPSHD-UHFFFAOYSA-N 0.000 description 2
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- YISRPYKYTBBHBK-ZCFIWIBFSA-N (1r)-3-chloro-1-thiophen-2-ylpropan-1-ol Chemical compound ClCC[C@@H](O)C1=CC=CS1 YISRPYKYTBBHBK-ZCFIWIBFSA-N 0.000 description 1
- QRYPRIQTWTYTGD-LURJTMIESA-N (3s)-3-hydroxy-3-thiophen-2-ylpropanenitrile Chemical compound N#CC[C@H](O)C1=CC=CS1 QRYPRIQTWTYTGD-LURJTMIESA-N 0.000 description 1
- IWYDHOAUDWTVEP-ZETCQYMHSA-N (S)-mandelic acid Chemical compound OC(=O)[C@@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-ZETCQYMHSA-N 0.000 description 1
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- PONXTPCRRASWKW-UHFFFAOYSA-N 1,2-diphenylethane-1,2-diamine Chemical compound C=1C=CC=CC=1C(N)C(N)C1=CC=CC=C1 PONXTPCRRASWKW-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- CWLKTJOTWITYSI-UHFFFAOYSA-N 1-fluoronaphthalene Chemical compound C1=CC=C2C(F)=CC=CC2=C1 CWLKTJOTWITYSI-UHFFFAOYSA-N 0.000 description 1
- ARNKHYQYAZLEEP-UHFFFAOYSA-N 1-naphthalen-1-yloxynaphthalene Chemical compound C1=CC=C2C(OC=3C4=CC=CC=C4C=CC=3)=CC=CC2=C1 ARNKHYQYAZLEEP-UHFFFAOYSA-N 0.000 description 1
- NNRUYUFRXMHMCU-UHFFFAOYSA-N 1-thiophen-2-ylprop-2-en-1-one Chemical compound C=CC(=O)C1=CC=CS1 NNRUYUFRXMHMCU-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- MXZROAOUCUVNHX-UHFFFAOYSA-N 2-Aminopropanol Chemical compound CCC(N)O MXZROAOUCUVNHX-UHFFFAOYSA-N 0.000 description 1
- MFPZQZZWAMAHOY-UHFFFAOYSA-N 2-Propanoylthiophene Chemical compound CCC(=O)C1=CC=CS1 MFPZQZZWAMAHOY-UHFFFAOYSA-N 0.000 description 1
- NOTCQEKRIPQPAW-UHFFFAOYSA-N 3-(2,2,2-trifluoroethoxy)prop-1-ene Chemical compound FC(F)(F)COCC=C NOTCQEKRIPQPAW-UHFFFAOYSA-N 0.000 description 1
- FRXLFVNGTPQFEJ-UHFFFAOYSA-N 3-bromopropanoyl bromide Chemical compound BrCCC(Br)=O FRXLFVNGTPQFEJ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- AMKGKYQBASDDJB-UHFFFAOYSA-N 9$l^{2}-borabicyclo[3.3.1]nonane Chemical compound C1CCC2CCCC1[B]2 AMKGKYQBASDDJB-UHFFFAOYSA-N 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- VJVQKGYHIZPSNS-FXQIFTODSA-N Ala-Ser-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N VJVQKGYHIZPSNS-FXQIFTODSA-N 0.000 description 1
- 244000300657 Alchornea rugosa Species 0.000 description 1
- 102000005751 Alcohol Oxidoreductases Human genes 0.000 description 1
- 108010031132 Alcohol Oxidoreductases Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- HCAUEJAQCXVQQM-ACZMJKKPSA-N Asn-Glu-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HCAUEJAQCXVQQM-ACZMJKKPSA-N 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000589513 Burkholderia cepacia Species 0.000 description 1
- CGKRFDXHYBJWPO-UHFFFAOYSA-N C(C)[AlH]CC.[Na] Chemical compound C(C)[AlH]CC.[Na] CGKRFDXHYBJWPO-UHFFFAOYSA-N 0.000 description 1
- HVGFPUCHCQWPPG-UHFFFAOYSA-N CC(C)C(C)BC(C)C(C)C.CC(C)C(C)BC(C)C(C)C Chemical compound CC(C)C(C)BC(C)C(C)C.CC(C)C(C)BC(C)C(C)C HVGFPUCHCQWPPG-UHFFFAOYSA-N 0.000 description 1
- FTYMOWXSFNYJSK-UHFFFAOYSA-N COCCO[AlH]OCCOC.[Li] Chemical compound COCCO[AlH]OCCOC.[Li] FTYMOWXSFNYJSK-UHFFFAOYSA-N 0.000 description 1
- HCQLWNQBTRWRPK-QMMMGPOBSA-N C[C@@H](CCNC)c1ccc[s]1 Chemical compound C[C@@H](CCNC)c1ccc[s]1 HCQLWNQBTRWRPK-QMMMGPOBSA-N 0.000 description 1
- 241000222173 Candida parapsilosis Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000177202 Chimonobambusa utilis Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000242346 Constrictibacter antarcticus Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 241000178292 Geotrichum clavatum Species 0.000 description 1
- 241000178290 Geotrichum fermentans Species 0.000 description 1
- CBEUFCJRFNZMCU-SRVKXCTJSA-N Glu-Met-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O CBEUFCJRFNZMCU-SRVKXCTJSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- ZZJVYSAQQMDIRD-UWVGGRQHSA-N Gly-Pro-His Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O ZZJVYSAQQMDIRD-UWVGGRQHSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- RXVOMIADLXPJGW-GUBZILKMSA-N His-Asp-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O RXVOMIADLXPJGW-GUBZILKMSA-N 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- RGHNJXZEOKUKBD-KLVWXMOXSA-N L-gluconic acid Chemical compound OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O RGHNJXZEOKUKBD-KLVWXMOXSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 241001468191 Lactobacillus kefiri Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 244000025090 Lactobacillus sanfrancisco Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 238000006683 Mannich reaction Methods 0.000 description 1
- 238000003612 Meerwein-Ponndorf-Verley reduction reaction Methods 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 241001655308 Nocardiaceae Species 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- PYOHODCEOHCZBM-RYUDHWBXSA-N Phe-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 PYOHODCEOHCZBM-RYUDHWBXSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010011939 Pyruvate Decarboxylase Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 229910003798 SPO2 Inorganic materials 0.000 description 1
- 101100434411 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) ADH1 gene Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 101100478210 Schizosaccharomyces pombe (strain 972 / ATCC 24843) spo2 gene Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000204060 Streptomycetaceae Species 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- GQPQJNMVELPZNQ-GBALPHGKSA-N Thr-Ser-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N)O GQPQJNMVELPZNQ-GBALPHGKSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- LUMQYLVYUIRHHU-YJRXYDGGSA-N Tyr-Ser-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LUMQYLVYUIRHHU-YJRXYDGGSA-N 0.000 description 1
- FZADUTOCSFDBRV-RNXOBYDBSA-N Tyr-Tyr-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=C(O)C=C1 FZADUTOCSFDBRV-RNXOBYDBSA-N 0.000 description 1
- GVJUTBOZZBTBIG-AVGNSLFASA-N Val-Lys-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N GVJUTBOZZBTBIG-AVGNSLFASA-N 0.000 description 1
- 229910021553 Vanadium(V) chloride Inorganic materials 0.000 description 1
- ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FWXAUDSWDBGCMN-DNQXCXABSA-N [(2r,3r)-3-diphenylphosphanylbutan-2-yl]-diphenylphosphane Chemical compound C=1C=CC=CC=1P([C@H](C)[C@@H](C)P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 FWXAUDSWDBGCMN-DNQXCXABSA-N 0.000 description 1
- 241000222124 [Candida] boidinii Species 0.000 description 1
- JFBZPFYRPYOZCQ-UHFFFAOYSA-N [Li].[Al] Chemical compound [Li].[Al] JFBZPFYRPYOZCQ-UHFFFAOYSA-N 0.000 description 1
- JEDZLBFUGJTJGQ-UHFFFAOYSA-N [Na].COCCO[AlH]OCCOC Chemical compound [Na].COCCO[AlH]OCCOC JEDZLBFUGJTJGQ-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 101150102866 adc1 gene Proteins 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005234 alkyl aluminium group Chemical group 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 238000009739 binding Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000012707 chemical precursor Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005356 chiral GC Methods 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 125000001309 chloro group Chemical class Cl* 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- AVPBPSOSZLWRDN-UHFFFAOYSA-M chloropalladium(1+);methanidylbenzene;triphenylphosphane Chemical compound [Pd+]Cl.[CH2-]C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 AVPBPSOSZLWRDN-UHFFFAOYSA-M 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 239000002734 clay mineral Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- SHFGJEQAOUMGJM-UHFFFAOYSA-N dialuminum dipotassium disodium dioxosilane iron(3+) oxocalcium oxomagnesium oxygen(2-) Chemical compound [O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Na+].[Na+].[Al+3].[Al+3].[K+].[K+].[Fe+3].[Fe+3].O=[Mg].O=[Ca].O=[Si]=O SHFGJEQAOUMGJM-UHFFFAOYSA-N 0.000 description 1
- WADSLQQIOJIXTB-UHFFFAOYSA-L dichloroalumane Chemical class Cl[AlH]Cl WADSLQQIOJIXTB-UHFFFAOYSA-L 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000011982 enantioselective catalyst Substances 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- BBIDBFWZMCTRNP-UHFFFAOYSA-N ethylalumane Chemical compound CC[AlH2] BBIDBFWZMCTRNP-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108010042598 glutamyl-aspartyl-glycine Proteins 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000006458 gyp medium Substances 0.000 description 1
- 150000002366 halogen compounds Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000007210 heterogeneous catalysis Methods 0.000 description 1
- 239000002638 heterogeneous catalyst Substances 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 238000009905 homogeneous catalytic hydrogenation reaction Methods 0.000 description 1
- BICAGYDGRXJYGD-UHFFFAOYSA-N hydrobromide;hydrochloride Chemical compound Cl.Br BICAGYDGRXJYGD-UHFFFAOYSA-N 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- MEUKEBNAABNAEX-UHFFFAOYSA-N hydroperoxymethane Chemical compound COO MEUKEBNAABNAEX-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- CYPPCCJJKNISFK-UHFFFAOYSA-J kaolinite Chemical compound [OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[O-][Si](=O)O[Si]([O-])=O CYPPCCJJKNISFK-UHFFFAOYSA-J 0.000 description 1
- 229910052622 kaolinite Inorganic materials 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 108010056929 lyticase Proteins 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000004462 maize silage Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910001507 metal halide Inorganic materials 0.000 description 1
- 150000005309 metal halides Chemical class 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- ACFIXJIJDZMPPO-NCHANQSKSA-N nadph Chemical compound C1=CCC(C(=O)N)=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2[C@@H]([C@H](OP(O)(O)=O)[C@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NCHANQSKSA-N 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- BDOLXPFAFMNDOK-UHFFFAOYSA-N oxazaborolidine Chemical compound B1CCON1 BDOLXPFAFMNDOK-UHFFFAOYSA-N 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- RPESBQCJGHJMTK-UHFFFAOYSA-I pentachlorovanadium Chemical compound [Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[V+5] RPESBQCJGHJMTK-UHFFFAOYSA-I 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000010451 perlite Substances 0.000 description 1
- 235000019362 perlite Nutrition 0.000 description 1
- 229920001568 phenolic resin Polymers 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- ICZHJFWIOPYQCA-UHFFFAOYSA-N pirkle's alcohol Chemical compound C1=CC=C2C(C(O)C(F)(F)F)=C(C=CC=C3)C3=CC2=C1 ICZHJFWIOPYQCA-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000003579 shift reagent Substances 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000012419 sodium bis(2-methoxyethoxy)aluminum hydride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- QIQITDHWZYEEPA-UHFFFAOYSA-N thiophene-2-carbonyl chloride Chemical compound ClC(=O)C1=CC=CS1 QIQITDHWZYEEPA-UHFFFAOYSA-N 0.000 description 1
- 150000003577 thiophenes Chemical class 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QIWRFOJWQSSRJZ-UHFFFAOYSA-N tributyl(ethenyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C=C QIWRFOJWQSSRJZ-UHFFFAOYSA-N 0.000 description 1
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
- PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
Definitions
- the present invention relates to a process for the preparation of 3-methylamino-1- (thien-2-yl) propan-1-ol of the formula I.
- B stands for an n-fold negatively charged inorganic or organic acid residue and H n B for a pharmaceutically acceptable acid.
- EP-B-0273658 describes a process for the preparation of the corresponding base of duloxetine by reacting 2-acetylthiophene in a Mannich reaction with formaldehyde and dimethylamine, reducing the keto group of the Mannich base thus obtained to racemic (S) -3- N, N-dimethylamino-1- (thien-2-yl) propan-1-ol, etherification of the alcohol function with naphthyl fluoride and finally Conversion of the dimethylamino group into a methylamino function.
- the desired enantiomer of the naphthyl ether is obtained by using chiral starting materials or by racemate separation at the end product stage, for example via the salts with optically active acids or chromatography on a chiral stationary phase.
- EP-A-0457559 also describes a method analogous to EP-B-0273658.
- the keto group of the Mannich base with the asymmetric reduction system LAH-Icb lithium aluminum hydride - [(2R, 2S) - (-) - 4-dimethylamino-1, 2-diphenyl-3-methyl-2-butanol]
- LAH-Icb lithium aluminum hydride - [(2R, 2S) - (-) - 4-dimethylamino-1, 2-diphenyl-3-methyl-2-butanol]
- the disadvantage of this is the sensitivity of the LAH-Icb reduction system, which is only stable for a few minutes.
- the object of the present invention was therefore to provide a process for the preparation of 3-methylamino-1- (thien-2-yl) propan-1-ol I which overcomes the disadvantages of the prior art described here.
- the object was achieved by first reacting thiophene in a Friedel-Crafts reaction with a .beta.-halogenopropionic acid halide or an acrylic acid halide in the presence of a Lewis acid, a hydrogen halide being introduced before the reaction product was isolated.
- the keto group of the 3-halo-1- (thien-2-yl) propan-1-one of the formula III obtained is then reduced
- Hai halogen and sets the reduced product of formula IV
- the present invention therefore relates to a process for the preparation of 3-methylamino-1- (thien-2-yl) propan-1-ol of the formula I.
- step b) the propanone obtained in step a) is reduced and then, preferably without isolation of the reaction product, reacted with methylamine.
- the process according to the invention gives the target compound I in good overall yields.
- the production of the intermediate halogen propanone IM is not linked to the use of expensive organotin reagents.
- the difficult to handle halogen propanol IV does not need to be isolated.
- the process allows an enantioselective preparation of the S enantiomer IS by simple means carry out the reduction of the halopropenone intermediate III in the presence of a chiral catalyst or a chiral reducing agent which have a selectivity with regard to the formation of (S) -3-halo-1- (thien-2-yl) propan-1-ol IS ,
- Enantioselectivity in the context of the present invention means that the enantiomeric excess ee (in%) of the S-enantiomer, which is calculated in a known manner according to:
- At least 50% is at least 50%, preferably at least 80%, in particular at least 90% and especially at least 95%.
- the end product of step a) is essentially no 1-thien-2-yl-propenone II, which is used in the processes of the prior art Technology always occurs as a by-product and reduces the yield of the desired acylation product III.
- Suitable Lewis acids are covalent metal halides and semimetal halides which have an electron pair gap. As a rule, they are selected from halogen compounds of titanium, tin, aluminum, vanadium, iron or boron.
- the chlorides are preferred; in the case of aluminum, however, the monoalkyl aluminum dichlorides and the dialkyl aluminum chlorides are also suitable. In the case of boron, the fluoride is also suitable.
- suitable Lewis acids are titanium tetrachloride, boron trichloride, boron trifluoride, tin tetrachloride, vanadium pentachloride, iron trichloride, aluminum trichloride, alkyl aluminum dichlorides and dialkyl aluminum chlorides. Aluminum trichloride is particularly preferably used.
- Suitable ß-halogenopropionic acid halides are 3-chloropropionic acid chloride and 3-bromopropionic acid bromide or chloride. 3-Chloropropionic acid chloride is preferably used.
- Acrylic acid chloride is preferably used as the acrylic acid halide.
- a ⁇ -halopropionic acid halide is preferably used as the acylating agent in step a).
- Suitable hydrogen halides are hydrogen chloride and hydrogen bromide.
- a hydrogen halide is preferably used in which the halogen atom corresponds to the ⁇ -halogen radical in the ⁇ -halogenopropionic acid halide used. Accordingly, when using 3-chloropropionic acid chloride, hydrogen chloride is preferably used.
- Suitable solvents for the reaction in step a) are all solvents which are usually used in Friedel-Crafts acylation reactions. overall In principle, aprotic solvents are suitable which do not reduce the reactivity of the reagents used, in particular the Lewis acid, or which do not enter into competitive reactions with the Lewis acid under the given reaction conditions.
- aromatic hydrocarbons which are significantly more difficult to acylate than thiophene, such as benzene, nitrobenzene and halogenated aromatic hydrocarbons, for example chlorobenzene and dichlorobenzene, and furthermore halogenated aliphatic hydrocarbons, in particular haloalkanes such as chloromethane, dichloromethane, chloroform, carbon tetrachloride, chloroethane, di- and trichloroethane. Mixtures of the abovementioned solvents are also suitable.
- Solvents in which the Friedel-Crafts acylation can proceed essentially homogeneously such as nitrobenzene or halogenated hydrocarbons, are preferably used.
- Halogenated aromatic or aliphatic hydrocarbons are particularly preferred, with haloalkanes being particularly preferred.
- dichloroethane or chlorobenzene is used.
- the Lewis acid must be used in at least equimolar amounts, based on the amount of acylated thiophene that can be theoretically achieved, since it forms a complex with the ketone formed during the acylation, which is stable under the usual reaction conditions of the Friedel-Crafts reaction , It is preferably in a molar ratio of 1: 1 to 1: 2, particularly preferably from 1: 1 to 1: 1, 5 and in particular from 1: 1, 1 to 1: 1, 5, based on 1 mol of the minor proportion used acylation component (thiophene or ß-halopropionic acid halide).
- Thiophene and the ß-halopropionic acid halide are used in a molar ratio of preferably 1: 0.5 to 1: 2, particularly preferably 1: 0.7 to 1: 1, 5 and in particular 1: 0.8 to 1: 1, 2 used.
- the order in which the reagents are combined in Friedel-Crafts acylation is of minor importance. For example, you can add the Lewis acid in the solvent and first add the ß-halopropionic acid halide and then the thiophene. Alternatively, one can submit thiophene and Lewis acid and add the ß-halopropionic acid halide.
- the reaction temperature is i.a. selected depending on the solvent. It is usually in the range from 10 ° C to 40 ° C.
- the reaction temperature is suitably at most 50 ° C., since otherwise the solvent itself will react.
- the reaction temperature is preferably from -20 ° C. to 40 ° C., particularly preferably from 0 to 30 ° C.
- reaction pressure is not critical. In general, the reaction is carried out at normal pressure; however, it can also be done with overpressure or underpressure.
- overpressure is used when the solvent is volatile or is not liquid under normal conditions, as is the case with chloromethane, for example.
- the hydrogen halide is preferably introduced after the acylation has taken place.
- the termination of the acylation reaction can be determined by conventional methods in the art, e.g. by gas chromatography, thin layer chromatography or NMR spectroscopy.
- the duration of the introduction depends, among other things, on the batch size and can be determined by the person skilled in the art in individual cases. As a rule, it is carried out at least until no more 1-thien-2-yl-propenone can be detected.
- the reaction mixture is generally first worked up hydrolytically in order to cleave the ketone-Lewis acid complex formed.
- Water or dilute aqueous mineral acids e.g. dilute hydrochloric acid. Further cleaning and isolation is carried out according to known methods, as described, for example, in Organikum, VEB Deutscher Verlag dermaschineen, 17th edition, 1988, p. 323 ff.
- step a) leads in step a) to a 3-halogeno- (thien-2-yl) -1-propanone III in high yields.
- Any 1-thien-2-yl-propenone II that may be formed in the course of the acylation reaction is essentially completely converted into the 3-halo- (thien-2-yl) -1-propanone III, so that the reaction mixture does not exceed 1 mole / o. particularly preferably at most 0.5 mol% propenone II, based on the yield of 3-halogeno- (thien-2-yl) -1-propanone III.
- step b) The reduction of propanone III in step b) is possible, for example, using a metal or semimetal hydride or using hydrogen in the presence of a suitable transition metal catalyst.
- Suitable metal or semimetal hydrides are both the neutral and the complex hydrides of metals or semimetals.
- Metal or semimetal hydrides which have proven themselves in the reduction of ketones to alcohols are advantageously used. They are preferably the hydrides of boron or aluminum.
- Suitable neutral hydrides are, for example, borane (BH 3 ; B 2 H 6 ), alan (AlH 3 ), silane (SiH 4 ), mono- and dialkylboranes, such as bis (3-methylbut-2-yl) borane (disiamylborane) or 9 -Borabicyclo [3.3.1] nonane (9-BBN), mono- and dialkylaluminium compounds such as diisobutylaluminium hydride (DIBAL-H), and trialkylsilanes such as trimethylsilane or triethylsilane.
- borane BH 3 ; B 2 H 6
- AlH 3 alan
- silane SiH 4
- mono- and dialkylboranes such as bis (3-methylbut-2-yl) borane (disiamylborane) or 9 -Borabicyclo [3.3.1] nonane (9-BBN)
- Suitable complex hydrides are, for example, complex borohydrides such as sodium borohydride (NaBH 4 ), lithium borohydride (LiBH 4 ) or calcium borohydride Ca [BH 4 ] 2 , complex aluminum hydrides such as ethyl aluminum hydride (LiAIH 4 ), complex alkyl or alkoxy borohydrides such as lithium triethyl borohydride or Kaliumtri ⁇ sopropoxyborhydrid
- Solvents suitable for reduction with metal or semimetal hydrides depend in particular on the reducing agent used and should of course not contain any groups which are also reduced under the reaction conditions.
- the reduction with the above-mentioned hydrides is preferably carried out in aprotic solvents without functional groups which can be reduced under the given reaction conditions.
- aromatic and aliphatic hydrocarbons for example C 5 -C 8 alkanes and C 5 -C 8 cycloalkanes, such as pentane, hexane, heptane, cyclopentane, cyclohexane and cyclooctane, aromatics, such as benzene, toluene, nitrobenzene, chloro- and Dichlorobenzene, furthermore open-chain and cyclic ethers with 4 to 8 carbon atoms, such as diethyl ether, methyl tert-butyl ether, tetrahydrofuran or dioxane, furthermore chlorinated hydrocarbons, in particular haloalkanes, such as chloromethane, dichloromethane, chloroform, carbon tetrachloride, di- or trichloroethane. Mixtures of the abovementioned solvents are also suitable.
- the reduction with some of the above-mentioned complex hydrides, in particular with less reactive hydrides, such as sodium borohydride, is also possible in the presence of protic solvents, for example CrC 3 alcohols, such as methanol, ethanol, propanol or isopropanol, or even in aqueous solution.
- protic solvents for example CrC 3 alcohols, such as methanol, ethanol, propanol or isopropanol, or even in aqueous solution.
- a mixture of at least one of the abovementioned aprotic solvents and at least one alcohol is preferably used.
- the reaction is preferably carried out in the presence of a suitable base when using protic solvents.
- Suitable bases are, for example, alkali metal hydroxides, such as sodium or potassium hydroxide, or alkylimetal carbonates, such as sodium or potassium carbonate.
- Sodium hydroxide is preferably used.
- the reduction with many of the metal or semimetal hydrides mentioned above is often exothermic, so that the reaction is suitably carried out with removal of the heat of reaction, i.e. is carried out with cooling.
- the reaction temperature is preferably -50 to 40 ° C, particularly preferably -30 to 30 ° C and in particular - 20 to 20 ° C.
- the reduction can be carried out by customary methods of the prior art, as described, for example, in Organikum, VEB Deutscher Verlag dermaschineen, 17th edition, 1988, p. 492 ff.
- the propanone III is initially introduced and the reducing agent is added in portions.
- Propanone III can also be reduced, for example, with an aluminum alcoholate.
- the reduction of ketones with an aluminum alcoholate is usually referred to as Meerwein-Ponndorf-Verley reduction.
- a ketone is in the corresponding alcohol is transferred and the alcoholate is simultaneously oxidized to the corresponding aldehyde (in the case of alcoholates of primary alcohols) or ketone (in the case of alcoholates of secondary alcohols).
- the reaction can be carried out by known methods, as described, for example, in Organikum, VEB Deutscher Verlag dermaschineen, 17th edition, 1988, pp. 486 ff.
- the reduction of propanone III is also achieved by catalytic hydrogenation, i.e. by reacting propanone III with hydrogen in the presence of suitable transition metal catalysts.
- suitable transition metals include the metals of subgroups VIII, VI and I, in particular platinum, ruthenium, copper, chromium and nickel.
- the catalysts must of course be chosen so that they do not catalyze / hydrogenate the thiophene group.
- the catalysts can be used both as heterogeneous and as homogeneous catalysts. Suitable processes are known in principle and, for example, in transition metals in organic synthesis. M. Beller, C. Bolm, Wiley-VCH, Weinheim, 1998, Volume 2, page 1 ff. (Homogeneous catalysts) and page 81 ff. (Heterogeneous catalysts).
- step b) is preferably carried out with a metal or semimetal hydride and particularly preferably with one of the complex metal or semimetal hydrides mentioned above.
- Sodium borohydride is especially used.
- the process according to the invention is used to prepare (S) -3-methylamino-1- (thien-2-yl) propan-1-ol of the formula I-S
- step b) being carried out in the presence of a chiral reducing agent or a chiral catalyst which has a selectivity with regard to the formation of (S) -3 -Methylamino-1- (thien-2-yl) propan-1-ol IS.
- step b) uses, for example, an asymmetric metal or semimetal hydride as the reducing agent or the reduction is carried out in the presence of an asymmetric induction-imparting compound.
- the asymmetrical metal or semimetal hydrides are preferably asymmetrical aluminum, boron or silicon hydrides.
- Suitable asymmetric borohydrides are described, for example, in E. J. Corey, C. J. Helal, Angew. Chem. 1998, 110, 2092-2118 or in MM Midland, LA Morell, Methods Org. Chem., Houben-Weyl, 4th edition, Volume E 21d, pp. 4082-4098, 1995, whereupon in full Reference is made.
- Suitable asymmetric silicon hydrides are described, inter alia, in H. Brunner, Methods Org. Chem., Houben-Weyl, 4th Edition, Volume E21d, pp. 4074-4081, 1995, to which reference is also made in full.
- asymmetrical induction-imparting compounds are understood to be those which are influenced by influencing the actual reducing agent, e.g. design the reduction of the propanone IM enantioselectively by forming bonds or complexing with the reducing agent or by taking up a hydrogen atom or another reductive component from the reducing agent.
- the compounds imparting asymmetrical induction themselves are not reducing.
- this includes asymmetric hydrogenation catalysts.
- hydrogen serves as the actual reducing agent, while the asymmetric catalyst favors the enantioselective formation of one of the possible enantiomers.
- the hydrogenation can take place both in a heterogeneous and in a homogeneous phase.
- Suitable catalysts for asymmetric hydrogenation in the heterogeneous phase are described, for example, in A. Baiker, HU Blaser in the Handbook of Heterogeneous Catalysis, Volume 5 (edited by G. Ertl, H. Knörzinger, J.Weitkamp), Wiley-VCH, Weinheim, 1997 , 2422-2436, which is hereby incorporated by reference in its entirety.
- Catalysts which contain a metal from subgroup VIII, for example platinum or ruthenium, in particular ruthenium, and at least one phosphorus-containing ligand are particularly suitable. Suitable catalysts are described, for example, in R. Noyori, T. Ohkuma, Angew. Chem. 2001, 113, 40-75, to which reference is hereby made in full. Ruthenium (II) diamine complexes are particularly suitable, in which the ruthenium is also bound to a bidentate chiral diphosphine ligand.
- a metal from subgroup VIII for example platinum or ruthenium, in particular ruthenium, and at least one phosphorus-containing ligand.
- Suitable catalysts are described, for example, in R. Noyori, T. Ohkuma, Angew. Chem. 2001, 113, 40-75, to which reference is hereby made in full.
- Ruthenium (II) diamine complexes are particularly suitable, in which the rut
- diphosphine ligands which are suitable for the reduction of the halogen propanone III to the S-halogen propanol IV-S are (R) -BINAP of the formula A, (R, R) -DIOP of the formula B and (R, R) -CHIRAPHOS the Formula C.
- Ph phenyl 4-methylphenyl (TolBINAP) 3,5-dimethylphenyl (XylBINAP)
- particularly preferred catalysts contain a diamine ligand.
- suitable diamine ligands are 1,2-ethylenediamine, 1,2-diphenyl-1,2-ethylenediamine and 1,2-cyclohexanediamine in their enantiomeric forms.
- the hydrogenation is usually carried out under the previously described conditions.
- a particularly preferred asymmetric induction-imparting compound is the oxazaborylidine of the formula D.
- R is C-
- the oxazaborylidine is generally used in catalytic amounts for the reduction.
- the borane is used in at least equimolar amounts, based on the halopropane III, but preferably in excess.
- the reaction usually takes place in suitable solvents. Suitable solvents are aprotic solvents. solvents that have no reducible groups under the given reaction conditions. These include in particular the aforementioned haloalkanes, aromatics and cyclic or acyclic ethers. Ether is preferably used, with tetrahydrofuran being particularly preferred.
- the reaction temperature is preferably -80 to 20 ° C, particularly preferably -30 to 10 ° C.
- the procedure is usually such that the oxazaborylidine is initially introduced in the solvent and either the borane and then the halopropane III or, conversely, first the halopropane III and then the borane are added at the desired reaction temperature, the first addition mode being preferred.
- the reaction time depends, among other things, on the batch size and can be determined in a particular case by a person skilled in the art.
- the catalyst or excess reducing agent used is deactivated or removed in the process according to the invention, depending on the reduction process used.
- this is usually done by hydrolysis, for example with an aqueous or alcoholic solution.
- the use of homogeneous hydrogenation catalysts or the reduction with aluminum alcoholates is also often carried out hydrolytically. If the reduction takes place in the form of a catalytic hydrogenation in a heterogeneous phase or with an enzyme as the reducing agent, the catalyst or the enzyme can be separated by physical separation, e.g. can be removed by decanting or filtration.
- homogeneous reduction systems in particular when reducing with metal or semimetal hydrides, however, it is preferably initially not deactivated.
- methylamine is added to the reaction mixture, which may be deactivated or separated from heterogeneous reduction systems, and is preferably reacted at elevated temperature, for example at 30 to 80 ° C., in particular at 50 to 70 ° C.
- the methylamine can be used either in gaseous form or as an aqueous solution, the use as an aqueous solution being preferred.
- reaction is preferably carried out at a pressure of 1 to 250 bar and in particular under the autogenous pressure which the system generates itself.
- reaction mixture After reaction with methylamine, the reaction mixture is worked up in the usual way. If this is not done before adding methylamine, te, the catalyst or the reducing agent is deactivated and separated as already described, the solvent is removed and clean methylaminopropanol I is isolated from the residue, for example by crystallization, digesting, extraction or chromatography.
- step a) of the process no expensive or time-consuming reagents or solvents are required and the halopropane III is produced in very high yields.
- step b) the isolation of the sensitive halogen propanol IV and a loss of yield associated therewith or the difficult handling of the halogen propanol IV are avoided.
- the S-enantiomer of methylaminopropanol I-S which is essential for the further conversion to duloxetine, can be obtained selectively with the process according to the invention if the reduction takes place in step b) with a chiral reducing agent.
- the present invention further relates to a process for the preparation of (S) -3-methylamino-1- (thien-2-yl) propan-1-ol of the formula IS, in which a 3-halo-1- (Thien-2-yl) propan-1-one III is reduced enantioselectively, characterized in that the reduction takes place in the presence of a dehydrogenase.
- the (S) -3-halo-1- (thien-2-yl) propan-1-ol IV-S obtained is reacted with methylamine without isolation.
- Suitable dehydrogenases are above all dehydrogenases (EG 1.1.1.x), in particular alcohol dehydrogenases (EC1.1 .1.1 or EG1.1.1.2), which bring about the selective reduction of halogen propanone III to S-halogen propanol IV-S .
- the dehydrogenase is preferably obtained from a microorganism, particularly preferably from a bacterium, a fungus, in particular a yeast, deposited in stock collections or obtainable from isolates from a natural source, such as soil samples, biomass samples and the like.
- the dehydrogenase comes from a yeast or a lactic acid bacterium.
- the dehydrogenase can be used in purified or partially purified form or in the form of the microorganism itself.
- Methods for obtaining and purifying dehydrogenases from microorganisms are well known to the person skilled in the art, for example from K. Nakamura & T. Matsuda, "Reduction of Ketones" in K. Drauz and H. Waldmann, Enzyme Catalysis in Organic Synthesis 2O02, Vol. III, 991-1032, Wiley-VCH, Weinheim, recombinant processes for the production of dehydrogenases are also known, for example from W. Hummel, K. Abokitse, K. Drauz, C. Rollmann and H. Gröger, Adv. Synth. Catal.
- Suitable bacteria are, for example, those of the genus Pseudomonas, Burkholderia, Agrobacterium, Rhodococcus, Lactobacillus or Lactococcus.
- Suitable yeasts are, for example, those of the genus Geotrichum, Pichia, Candida, Hansenula or Saccharomyces.
- Dehydrogenases from yeast and lactic acid bacteria are particularly preferably used. Preferred among these are dehydrogenases which are obtained from yeasts of the genus Geotrichum or Candida or which are obtained from lactic acid bacteria of the genus Lactobacillus or Lactococcus.
- Lactobacillus species are L. brevis, L. kefir, L. plantarum, L. casei, L. acidophilus, L. delbrueckii and L. sanfrancisco.
- Candida species are C. magnoliae, C. rugosa, C. utilis, C. boidinii, C. parapsilosis and C. antarctica.
- Geotrichum species are G. candidum, G. clavatum and G. fermentans.
- Dehydrogenases from Candida magnoliae, Geotrichum candidum or Lactobacillus brevis are particularly preferably used.
- the reduction with the dehydrogenase usually takes place in the presence of a suitable coenzyme (also referred to as a cofactor).
- a suitable coenzyme also referred to as a cofactor
- NADH and / or NADPH is usually used as the coenzyme for the reduction of the ketone.
- dehydrogenases can be used as cellular systems which inherently contain cofactor, or alternative redox mediators can be added (A. Schmidt, F. Hollmann and B. Bühler "Oxidation of Alcohols" in K. Drauz and H. Waldmann, Enzyme Catalysis in Organic Synthesis 2002, Vol.lll, 991-1032, Wiley-VCH, Weinheim).
- the reduction with the dehydrogenase usually also takes place in the presence of a suitable cosubstrate, which generally acts as a reducing agent for the coenzyme oxidized in the course of the reduction and thus regenerates it.
- suitable cosubstrates are sugar, in particular hexoses, such as glucose, mannose, fructose, and / or oxidizable alcohols, in particular ethanol, propanol or isopropanol, and formate.
- a second dehydrogenase e.g. Glucose dehydrogenase can be added when using glucose as cosubstrate. This can be used as a free or immobilized enzyme or in the form of free or immobilized cells. They can be produced either separately or by coexpression in a (recombinant) dehydrogenase strain.
- the dehydrogenases used according to the invention can be used freely or immobilized.
- An immobilized enzyme is an enzyme that is fixed to an inert carrier. Suitable carrier materials and the enzymes immobilized thereon are known from EP-A-1149849, EP-A-1 069 183 and DE-OS 100193773 and from the references cited therein. Revelation this publication is referred to in its entirety in this regard.
- Suitable carrier materials include, for example, clays, clay minerals, such as kaolinite, diatomaceous earth, perlite, silicon dioxide, aluminum oxide, sodium carbonate, calcium carbonate, cellulose powder, anion exchange materials, synthetic polymers, such as polystyrene, acrylic resins, phenol formaldehyde resins, polyurethanes and polyolefins, such as polyolefins ethylene and polypropylene.
- the carrier materials are usually used in a finely divided, particulate form for the production of the supported enzymes, with porous forms being preferred.
- the particle size of the carrier material is usually not more than 5 mm, in particular not more than 2 mm (sieve line).
- Carrier materials are, for example, Ca alginate and Carrageenan.
- Enzymes as well as cells can also be cross-linked directly with glutaraldehyde (cross-linking to CLEAs). Corresponding and further immobilization methods are described, for example, in J. Lalonde and A. Margolin “Immobilization of Enzymes” in K. Drauz and H. Waldmann, Enzyme Catalysis in Organic Synthesis 2002, Vol. III, 991-1032, Wiley-VCH, Weinheim.
- the reduction reaction can take place in aqueous or non-aqueous reaction media or in 2-phase systems or (micro) emulsions.
- the aqueous reaction media are preferably buffered solutions which generally have a pH of 5 to 8, preferably 6 to 8.
- the aqueous solvent can also contain at least one alcohol, e.g. Contain ethanol or isopropanol.
- Non-aqueous reaction media are to be understood as meaning reaction media which contain less than 1% by weight, preferably less than 0.5% by weight, of water, based on the total weight of the reaction medium.
- the reaction is preferably carried out in an organic solvent.
- Suitable solvents are, for example, aliphatic hydrocarbons, preferably having 5 to 8 carbon atoms, such as pentane, cyclopentane, hexane, cyclohexane, heptane, octane or cyclooctane, halogenated aliphatic hydrocarbons, preferably having one or two carbon atoms, such as dichloromethane, chloroform, carbon tetrachloride, dichloroethane or tetrachloroethane, aromatic hydrocarbons, such as benzene, toluene, the xylenes, chlorobenzene or dichlorobenzene, aliphatic acyclic and cyclic
- the reduction with the dehydrogenase is carried out in an aqueous-organic, in particular aqueous, reaction medium.
- the halogen propanone III is preferably used in the concentration of 0.1 g / l to 500 g / l, particularly preferably from 1 g / l to 50 g / l, and can be added continuously or discontinuously.
- the enzymatic reduction is generally carried out at a reaction temperature below the deactivation temperature of the dehydrogenase used and preferably at at least -10 ° C. It is particularly preferably in the range from 0 to 100 ° C., in particular from 15 to 60 ° C. and especially from 20 to 40 ° C., for example around 30 ° C.
- the halogen propanone III with the dehydrogenase, the solvent and, if appropriate, the coenzymes, optionally an auxiliary dehydrogenase for regeneration of the coenzyme and / or further co-substrates, and the mixture, for. B. by stirring or shaking.
- the keto group of the halopropane III is reduced to an OH group, the S-enantiomer of the halopropanol IV-S being formed essentially selectively.
- the reduction will lead to a conversion of at least 70%, particularly preferably of at least 85% and in particular of at least 95%, based on the halogenated propanone III contained in the mixture.
- the progress of the reaction, i. H. the sequential reduction of the ketone can be followed by conventional methods such as gas chromatography.
- Alcohol dehydrogenases with at least one of the following properties are particularly preferably used as dehydrogenases in the process according to the invention:
- Alcohol dehydrogenases with an amino acid sequence that has a partial amino acid sequence of at least 5, 6, 7 or 8, preferably at least 10, e.g. 10, 11, 12, 13, 14, or 15, consecutive amino acid residues according to SEQ ID NO: 1, wherein preferably the position corresponding to amino acid position 12 according to SEQ ID NO: 1 stands for valine; or b) a partial amino acid sequence of at least 5, 6, 7 or 8, preferably at least 10, e.g. 10, 11, 12, 13, 14, or 15, consecutive amino acid residues according to SEQ ID NO: 2; and functional equivalents thereof.
- Alcohol dehydrogenases which catalyzes the reduction in an enantiomeric purity of at least 85% ee (in the presence of NADH and / or NADPH; at 30 ° C. and pH 6.0).
- Alcohol dehydrogenases which are encoded by a nucleic acid sequence comprising SEQ ID NO: 3, or which comprise an amino acid sequence according to SEQ ID NO: 4 or at least a partial sequence according to FIG. 3, and preferably from Lactobacillus brevis are available; as well as the functionally equivalent alcohol dehydrogenases derived therefrom.
- Alcohol dehydrogenases which are encoded by a nucleic acid sequence comprising SEQ ID NO: 5 or which have an amino acid sequence comprising SEQ ID NO: 6 and which are preferably obtainable from Candida magnoliae (ATCC 1 2573); as well as the functionally equivalent alcohol dehydrogenases derived therefrom.
- Another object of the present invention is also a (S) -3-chloro-1- (thien-2-yl) propan-1-ol dehydrogenase with at least one of the properties listed above.
- the temperature stability range of the dehydrogenase is preferably from 10 to 80 ° C.
- the temperature optimum of their activity is preferably in the range from 20 to 60 ° C., particularly preferably from 25 to 40 ° C.
- the pH stability range is preferably pH 4 to 10.
- the optimal pH for dehydrogenation is preferably in the range of pH 5 to 8.
- the dehydrogenase according to the invention is preferably for the dehydrogenation of (S) -3-chloro-1- (thien-2-yl) -propan-1-ol to 3-chloro-1- (thien-2-yl) - propan-1- one in the presence of NAD + or NADP + . It preferably has a molecular weight in the range of 30 ⁇ 2 kDaltons.
- the present invention also relates to a nucleic acid sequence, comprising the coding sequence for the dehydrogenase according to the invention or a coding partial sequence.
- a nucleic acid sequence comprising the coding sequence for the dehydrogenase according to the invention or a coding partial sequence.
- a non-limiting example of this is the sequence shown in SEQ ID NO: 3 or 6.
- the present invention furthermore relates to an expression cassette comprising the nucleic acid sequence according to the invention in operative linkage with at least one regulatory nucleic acid sequence.
- the present invention furthermore relates to a recombinant vector comprising at least one expression cassette according to the invention.
- the present invention also relates to a prokaryotic or eukaryotic host, transformed with at least one vector according to the invention.
- the present invention relates to the use of the dehydrogenase according to the invention or a microorganism producing this dehydrogenase for the production of (S) -3-halo-1- (thien-2-yl) propan-1-ol and in particular for the production of Duloxetine.
- dehydrogenases also included according to the invention are “functional equivalents” of the specifically disclosed enzymes with (S) -3-chloro-1- (thien-2-yl) propan-1-ol dehydrogenase activity and the use thereof in the method according to the invention.
- “Functional equivalents” or analogs of the specifically disclosed enzymes are, within the scope of the present invention, different polypeptides thereof which also have the desired biological activity, such as substrate specificity.
- “functional equivalents” are understood to mean enzymes which are derived from 3-chloro Reduce 1- (thien-2-yl) -propan-1-one to the corresponding S-alcohol and the at least 20%, preferably 50%, particularly preferably 75%, very particularly preferably 90% of the activity of an enzyme, comprising one of the below SEQ ID NO: 1, 2, 4 or 6 amino acid sequences listed or shown in FIG. 3.
- Functional equivalents are also preferably stable between pH 4 to 10 and advantageously have a pH optimum between pH 5 and 8 and a temperature optimum in the range from 20 ° C. to 80 ° C.
- “functional equivalents” are also understood to mean, in particular, mutants which, in at least one sequence position of the above-mentioned amino acid sequences, have a different amino acid than the one specifically mentioned, but nevertheless have one of the above-mentioned biological activities. “Functional equivalents” thus include those by a or several amino acid additions, substitutions, deletions and / or inversions available mutants, the changes mentioned being able to occur in any sequence position as long as they lead to a mutant with the property profile according to the invention. Functional equivalence is particularly given when the reactivity patterns between mutant and unchanged polypeptide match qualitatively, i.e. For example, the same substrates can be implemented at different speeds.
- Precursors are natural or synthetic precursors of the polypeptides with or without the desired biological activity.
- salts means both salts of carboxyl groups and acid addition salts of amino groups of the protein molecules according to the invention.
- Salts of carboxyl groups can be prepared in a manner known per se and include inorganic salts, such as sodium, calcium, ammonium , Iron and zinc salts, and salts with organic bases, such as, for example, amines, such as triethanolamine, arginine, lysine, piperidine and the like, acid addition salts, such as, for example, salts with mineral acids, such as hydrochloric acid or sulfuric acid, and salts with organic acids, such as acetic acid and Oxalic acid are also the subject of the invention.
- inorganic salts such as sodium, calcium, ammonium , Iron and zinc salts
- organic bases such as, for example, amines, such as triethanolamine, arginine, lysine, piperidine and the like
- acid addition salts such as, for example, salts with mineral acids, such as hydrochloric acid or sulfuric
- “Functional derivatives” of polypeptides according to the invention can also be prepared on functional amino acid side groups or on their N- or C-terminal end using known techniques. Such derivatives include, for example, aliphatic esters of carboxylic acid groups, amides of carboxylic acid groups, obtainable by reaction with ammonia or with a primary or secondary amine; N-acyl derivatives of free amino groups, produced by reaction with acyl groups; or O-acyl derivatives of free hydroxyl groups, produced by reaction with acyl groups.
- “functional equivalents” according to the invention include proteins of the type described above in deglycosylated or glycosylated form and also modified forms obtainable by changing the glycosylation pattern.
- “Functional equivalents” naturally also include polypeptides that are accessible from other organisms, as well as naturally occurring variants. For example, regions of homologous sequence regions can be determined by sequence comparison and, based on the specific requirements of the invention, equivalent enzymes can be determined.
- “Functional equivalents” also include fragments, preferably individual domains or sequence motifs, of the polypeptides according to the invention which, for example, have the desired biological function.
- “Functional equivalents” are also fusion proteins which contain one of the polypeptide sequences mentioned above or functional equivalents derived therefrom and at least one further, functionally different, heterologous sequence in functional N- or C-terminal linkage (ie without mutual substantial functional impairment of the fusion protein parts)
- Non-limiting examples of such heterologous sequences are, for example, signal peptides or enzymes.
- “Functional equivalents” included according to the invention are homologs to the specifically disclosed proteins. These have at least 60%, preferably at least 75%, in particular at least 85%, such as 90%, 95%, 97% or 99%, homology to one of the specific ones Disclosed amino acid sequences, calculated according to the algorithm of Pearson and Lipman, Proc. Natl. Acad, Sci. (USA) 85 (8), 1988, 2444-2448.
- a percentage homology of a homologous polypeptide according to the invention means in particular percentage identity of the amino acid residues based on the Total length of one of the amino acid sequences specifically described herein.
- Homologs of the proteins or polypeptides according to the invention can be generated by mutagenesis, e.g. by point mutation or shortening of the protein.
- Homologs of the protein according to the invention can be identified by screening combinatorial banks of mutants, such as, for example, shortening mutants.
- a varied bank of protein variants can be generated by combinatorial mutagenesis at the nucleic acid level, such as, for example, by enzymatic ligation of a mixture of synthetic oligonucleotides.
- methods that can be used to generate banks of potential homologues from a degenerate oligonucleotide sequence. The chemical synthesis of a degenerate gene sequence can be carried out in an automatic DNA synthesizer, and the synthetic gene can then be ligated into a suitable expression vector.
- degenerate gene set makes it possible to provide all sequences in a mixture that contain the desired set encode potential protein sequences.
- Methods for the synthesis of degenerate oligonucleotides are known to the person skilled in the art (for example Narang, SA (1983) Tetrahedron 39: 3; Itakura et al. (1984) Annu. Rev. Biochem. 53: 323; Itakura et al., (1984) Science 198: 1056; Ike et al. (1983) Nucleic Acids Res. 11: 477).
- REM Recursive ensemble mutagenesis
- the invention relates in particular to nucleic acid sequences (single and double-stranded DNA and RNA sequences, such as cDNA and mRNA) which code for an enzyme with dehydrogenase activity according to the invention.
- nucleic acid sequences which e.g. code for amino acid sequences according to SEQ ID MO: 1, 2, 4, 6 or FIG. 3 or characteristic partial sequences thereof, or include nucleic acid sequences according to SEQ ID NO: 3 or 5 or characteristic partial sequences thereof.
- nucleic acid sequences mentioned herein can be produced in a manner known per se by chemical synthesis from the nucleotide building blocks, such as, for example, by fragment condensation of individual overlapping, complementary nucleic acid building blocks of the double helix.
- the chemical synthesis of oligonucleotides can be carried out, for example, in a known manner using the phosphoamidite method (Voet, Voet, 2nd edition, Wiley Press New York, pages 896-897).
- the addition of synthetic oligonucleotides and the filling of gaps with the aid of the Klenow fragment of DNA polymerase and ligation reactions as well as general cloning methods are described in Sambrook et al. (1989) Molecular Cloning: A laboratory manual, Cold Spring Harbor Laboratory Press.
- the invention also relates to nucleic acid sequences (single and double-stranded DNA and RNA sequences, such as cDNA and mRNA) coding for one of the above polypeptides and their functional equivalents, which are accessible, for example, using artificial nucleotide analogs.
- the invention relates both to isolated nucleic acid molecules which code for polypeptides or proteins or biologically active sections thereof, and to nucleic acid fragments which e.g. can be used as hybridization probes or primers for the identification or amplification of coding nucleic acids according to the invention.
- nucleic acid molecules according to the invention can also contain untranslated sequences from the 3 'and / or 5' end of the coding gene region
- the invention further comprises the nucleic acid molecules complementary to the specifically described nucleotide sequences or a section thereof.
- nucleotide sequences according to the invention enable the generation of probes and primers which can be used for the identification and / or cloning of homologous sequences in other cell types and organisms.
- probes or primers usually comprise a nucleotide sequence region which, under "stringent” conditions (see below), comprises at least about 12, preferably at least about 25, for example about 40, 50 or 75 successive nucleotides of a sense strand of a nucleic acid sequence according to the invention or of a corresponding antisense strand hybridizes.
- nucleic acid molecule is separated from other nucleic acid molecules that are present in the natural source of the nucleic acid and, moreover, can be substantially free of other cellular material or culture medium when produced by recombinant techniques, or free of chemical precursors or other chemicals be when it's chemically synthesized.
- a nucleic acid molecule according to the invention can be isolated using standard molecular biological techniques and the sequence information provided according to the invention.
- cDNA can be isolated from a suitable cDNA library by using one of the specifically disclosed complete sequences or a section thereof as a hybridization probe and standard hybridization techniques (as described, for example, in Sambrook, J., Fritsch, EF and Maniatis, T. Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).
- nucleic acid molecule comprising one of the disclosed sequences or a section thereof can be isolated by polymerase chain reaction, using the oligonucleotide primers which have been created on the basis of this sequence.
- the nucleic acid amplified in this way can be cloned into a suitable vector and characterized by DNA sequence analysis.
- the oligonucleotides according to the invention can also be produced by standard synthesis methods, for example using an automatic DNA synthesizer.
- the nucleic acid sequences according to the invention can be identified and isolated from all organisms.
- the nucleic acid sequences according to the invention or the homologues thereof can advantageously be isolated from fungi, yeasts or bacteria. Gram-negative and gram-positive bacteria are mentioned as bacteria.
- the nucleic acids according to the invention are preferably obtained from gram-negative bacteria, advantageously from alpha-proteobacteria, beta-proteobacteria or gamma-proteobacteria, particularly preferably from bacteria of the Enterobacteriaceae, Pseudomonadaceae or Rhizobiaceae families, very particularly preferably from bacteria of the genus Agrobacterium, Pseudomonas or Burkholderia above the Methods known to those skilled in the art are isolated.
- Nucleic acid sequences according to the invention can be obtained, for example, using conventional hybridization methods or the PCR technique from other fungi or bacteria, e.g. isolate via genomic or cDNA libraries. These DNA sequences hybridize under standard conditions with the sequences according to the invention. Short oligonucleotides of the conserved regions, for example from the active center, which can be determined in a manner known to the person skilled in the art by comparison with a dehydrogenase according to the invention, are advantageously used for the hybridization. However, longer fragments of the nucleic acids according to the invention or the complete sequences can also be used for the hybridization.
- DNA hybrids are approx. 10 ° C lower than those of DNA: RNA hybrids of the same length.
- DNA hybrids are advantageously 0.1 ⁇ SSC and temperatures between approximately 20 ° C. to 45 ° C., preferably between approximately 30 ° C. to 45 ° C.
- DNA: RNA hybrids the hybridization conditions are advantageously 0.1 x SSC and temperatures between about
- These specified temperatures for the hybridization are, for example, calculated melting temperature values for a nucleic acid with a length of approximately 100 nucleotides and a G + C content of 50% in the absence of formamide.
- the experimental conditions for DNA hybridization are described in relevant textbooks on genetics, such as, for example, Sambrook et al., "Molecular Cloning", Cold Spring Harbor Laboratory, 1989, and can be made according to formulas known to the person skilled in the art, for example depending on the length of the nucleic acids , the type of hybrid or the G + C content. The person skilled in the art can obtain further information on hybridization from the following textbooks: Ausubel et al.
- the invention also relates to derivatives of the specifically disclosed or derivable nucleic acid sequences.
- nucleic acid sequences according to the invention e.g. derived from SEQ ID NO: 3 or 5 and differ from them by addition, substitution, insertion or deletion of one or more nucleotides, but continue to code for polypeptides with the desired property profile.
- nucleic acid sequences which comprise so-called silent mutations or which have been changed in accordance with the codon usage of a specific source or host organism, in comparison to a specifically named sequence, as well as naturally occurring variants, such as e.g. Splice variants or allele variants, thereof.
- the invention also relates to the molecules derived from the specifically disclosed nucleic acids by sequence polymorphisms. These genetic polymorphisms can exist between individuals within a population due to natural variation. These natural variations usually cause a 1 to 5% variance in the nucleotide sequence of a gene.
- nucleic acid sequence is understood to mean, for example, allelic variants which have at least 40% homology at the derived amino acid level, preferably at least 60% homology, very particularly preferably at least 80, 85, 90, 93, 95 or 98% homology over the entire sequence range (for homology at the amino acid level, reference is made to the above statements on the polypeptides).
- allelic variants which have at least 40% homology at the derived amino acid level, preferably at least 60% homology, very particularly preferably at least 80, 85, 90, 93, 95 or 98% homology over the entire sequence range (for homology at the amino acid level, reference is made to the above statements on the polypeptides).
- the homologies can advantageously be higher over partial regions of the sequences.
- Derivatives are also to be understood to mean homologs of the nucleic acid sequences according to the invention, for example fungal or bacterial homologs, shortened sequences, single-stranded DNA or RNA of the coding and non-coding DNA sequence. At the DNA level, for example, they have a homology of at least 40%, preferably of at least 60%, particularly preferably of at least 70%, very particularly preferably of at least 80% over the entire specified DNA range. Derivatives are also to be understood, for example, as fusions with promoters.
- the promoters that precede the specified nucleotide sequences can be changed by one or more nucleotide exchanges, insertions, inversions and / or deletions, but without the functionality or effectiveness of the promoters being impaired. Furthermore, the effectiveness of the promoters can be increased by changing their sequence, or completely replaced by more effective promoters, including organisms of other species.
- Derivatives are also to be understood as variants whose nucleotide sequence in the range from -1 to -1000 bases upstream before the start codon or 0 to 100O bases downstream after the stop codon have been changed such that the gene expression and / or the protein expression is changed, preferably increased.
- the invention also encompasses nucleic acid sequences which hybridize with the coding sequences mentioned above under “stringent conditions”.
- This property means the ability of a poly- or oligonucleotide to bind to an almost complementary sequence under stringent conditions, while under these conditions non-specific bindings between non-complementary partners are avoided.
- the sequences should be 70-100%, preferably 90-100%, complementary.
- complementary sequences of being able to specifically bind to one another is used, for example, in the Northern or Southern blot technique or in the primer binding in PCR or RT-PCR. Usually oligonucleotides with a length of 30 base pairs or more are used for this.
- Stringent conditions mean, for example in Northern blot technology, the use of a washing solution which is 50-70 ° C., preferably 60-65 ° C., for example 0.1x SSC buffer with 0.1% SDS (20x SSC: 3M NaCl , 0.3M Na citrate, pH 7.0) for the elution of non-specifically hybridized cDNA probes or oligonucleotides.
- a washing solution which is 50-70 ° C., preferably 60-65 ° C., for example 0.1x SSC buffer with 0.1% SDS (20x SSC: 3M NaCl , 0.3M Na citrate, pH 7.0) for the elution of non-specifically hybridized cDNA probes or oligonucleotides.
- SDS 3M NaCl , 0.3M Na citrate, pH 7.0
- polynucleotides can be found in the screening of genomic or cDNA libraries and, if appropriate, can be multiplied therefrom by means of suitable primers by means of PCR and then isolated, for example, using suitable probes.
- polynucleotides according to the invention can also be synthesized chemically.
- the invention also relates to expression constructs containing, under the genetic control of regulatory nucleic acid sequences, a nucleic acid sequence coding for a polypeptide according to the invention; and vectors comprising at least one of these expression constructs.
- Such constructs according to the invention preferably comprise a promoter 5'-upstream of the respective coding sequence and a terminator sequence 3'-downstream and, if appropriate, further customary regulatory elements, in each case operatively linked to the coding sequence.
- operative linkage is understood to mean the sequential arrangement of promoter, coding sequence, terminator and, if appropriate, further regulatory elements in such a way that each of the regulatory elements can perform its function as intended in the expression of the coding sequence.
- sequences which can be linked operatively are Targeting sequences as well as enhancers, polyadenylation signals and the like.
- Further regulatory elements include selectable markers, amplification signals, origins of replication and the like. Suitable regulatory sequences are described, for example, in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA. (1990).
- a nucleic acid construct according to the invention is to be understood in particular to be those in which the gene for a dehydrogenase according to the invention has one or more regulation signals for control, e.g. Increase that gene expression has been operatively or functionally linked.
- the natural regulation of these sequences may still be present before the actual structural genes and may have been genetically modified so that the natural regulation has been switched off and the expression of the genes increased.
- the nucleic acid construct can also have a simpler structure, ie no additional regulation signals have been inserted in front of the coding sequence and the natural promoter with its regulation has not been removed. Instead, the natural regulatory sequence is mutated so that regulation no longer takes place and gene expression is increased.
- a preferred nucleic acid construct advantageously also contains one or more of the "enhancer" sequences already mentioned, functionally linked to the promoter, which enable increased expression of the nucleic acid sequence. Additional advantageous sequences, such as further regulatory elements or terminators, can also be inserted at the 3 'end of the DNA sequences.
- the nucleic acids according to the invention can be contained in the construct in one or more copies. Further markers, such as antibiotic resistance or genes complementing auxotrophies, may also be contained in the construct, optionally for selection on the construct.
- Advantageous regulatory sequences for the method according to the invention are, for example, in promoters such as cos, tac, trp, tet, trp-tet, Ipp, lac, Ipp-lac, lacl q " T7-, T5-, T3- , gal, trc, ara, rhaP (rhaP BAD ) SP6, lambda-P R - or in the lambda-P L - promoter, which are advantageously used in gram-negative bacteria grarn-positive promoters amy and SPO2, in the yeast or fungal promoters ADC1, MFalpha, AC, P-60, CYC1, GAPDH, TEF, rp28, ADH included.
- promoters of pyruvate decarboxylase and methanol oxide for example from Hansenula, are also advantageous. Artificial promoters can also be used for regulation.
- the nucleic acid construct is advantageously inserted into a vector, such as, for example, a plasmid or a phage, which enables optimal expression of the genes in the host.
- a vector such as, for example, a plasmid or a phage
- vectors are also to be understood as meaning all other vectors known to the person skilled in the art, for example viruses such as SV40, CMV, baculovirus and adenovirus, transposons, IS elements, phasmids, cosmids, and linear or circular DNA. These vectors can be replicated autonomously in the host organism or replicated chromosomally. These vectors represent a further embodiment of the invention. Suitable plasmids are, for example, in E.
- plasmids mentioned represent a small selection of the possible plasmids. Further plasmids are well known to the person skilled in the art and can be found, for example, in the book Cloning Vectors (Eds. Pouwels PH et al. Elsevier, Amsterdam-New York-Oxford, 1985, ISBN 0) 444 904018).
- the nucleic acid construct for the expression of the other genes contained additionally contains 3'- and / or 5'-terminal regulatory sequences for increasing expression, which are selected depending on the selected host organism and gene or genes for optimal expression.
- regulatory sequences are intended to enable targeted expression of the genes and protein expression. Depending on the host organism, this can mean, for example, that the gene is only expressed or overexpressed after induction, or that it is expressed and / or overexpressed immediately.
- the regulatory sequences or factors can preferably have a positive influence on the gene expression of the introduced genes and thereby increase it.
- the regulatory elements can advantageously be strengthened at the transcription level by using strong transcription signals such as promoters and / or "enhancers".
- an increase in translation is also possible, for example, by improving the stability of the mRNA.
- the vector containing the nucleic acid construct according to the invention or the nucleic acid according to the invention can also advantageously be introduced into the microorganisms in the form of a linear DNA and introduced into the genome of the host via heterologous or homologous recombination.
- This linear DNA can consist of a linearized vector such as a plasmid or only of the nucleic acid construct or the nucleic acid according to the invention.
- An expression cassette according to the invention is produced by fusing a suitable promoter with a suitable coding nucleotide sequence and a terminator or polyadenylation signal.
- Common recombination and cloning techniques such as those described in T. Maniatis, E.F. Fritsch and J. Sambrook, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1989) and in T.J. Silhavy, M.L. Berman and L.W. Enquist, Experiments with Gene Fusions, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1984) and in Ausubel, F.M. et al., Current Protocols in Molecular Biology, Greene Publishing Assoc. and Wiley Interscience (1987).
- the recombinant nucleic acid construct or gene construct is advantageously inserted into a host-specific vector which enables optimal expression of the genes in the host.
- Vectors are well known to the person skilled in the art and can be found, for example, from "Cloning Vectors" (Powels P.H. et al., Ed., Elsevier, Amsterdam-New York-Oxford, 1985).
- recombinant microorganisms can be produced which, for example, have been transformed with at least one vector according to the invention and can be used to produce the polypeptides according to the invention.
- the recombinant constructs according to the invention described above are advantageously introduced and expressed in a suitable host system.
- Common cloning and transfection methods known to the person skilled in the art such as, for example, co-precipitation, protoplast fusion, electroporation, retroviral transfection and the like, are preferably used to bring the nucleic acids mentioned into expression in the respective expression system. Suitable systems are described, for example, in Current Protocols in Molecular Biology, F.
- homologously recombined microorganisms can also be produced.
- a vector is produced which contains at least a section of a gene or a coding sequence according to the invention, in which optionally at least an amino acid deletion, addition or substitution has been introduced in order to change the sequence according to the invention, for example to disrupt functionally ("knock-out" vector).
- the introduced sequence can, for example, also be a homologue from a related microorganism or can be derived from a mammalian, yeast or insect source.
- the vector used for homologous recombination can alternatively be designed in such a way that the endogenous gene is mutated or otherwise altered in the case of homologous recombination, but still encodes the functional protein (for example the upstream regulatory region can be altered in such a way that the expression of the endogenous protein thereby is changed).
- the modified section of the gene according to the invention is in the homologous recombination vector.
- prokaryotic or eukaryotic organisms are suitable as recombinant host organisms for the nucleic acid according to the invention or the nucleic acid construct.
- Microorganisms such as bacteria, fungi or yeasts are advantageously used as host organisms.
- Gram-positive or gram-negative bacteria are preferred, preferably bacteria from the Enterobacteriaceae, Pseudomonadaceae, Rhizobiaceae, Streptomycetaceae or Nocardiaceae families, particularly preferably bacteria from the genera Escherichia, Pseudomonas, Streptomyces, Nocardia, Burkholderocacteria, Saliumella, Salmonella.
- the genus and species Escherichia coli is very particularly preferred.
- Further advantageous bacteria can also be found in the group of alpha-proteobacteria, beta-proteobacteria or gamma-proteobacteria.
- the host organism or the host organisms according to the invention preferably contain at least one of the nucleic acid sequences, nucleic acid constructs or vectors described in this invention, which code for an enzyme with dehydrogenase activity according to the invention.
- Microorganisms are usually in a liquid medium that contains a carbon source mostly in the form of sugars, a nitrogen source mostly in the form of organic nitrogen sources such as yeast extract or salts such as ammonium sulfate, trace elements such as iron, manganese, magnesium salts and possibly vitamins, at temperatures between 0 ° C and 100 ° C, preferably between 10 ° C to 60 ° C attracted with oxygen.
- the pH of the nutrient liquid can be kept at a fixed value, that is to say it can be regulated during cultivation or not.
- the cultivation can take place “batch”, “semi batch” or continuously.
- Nutrients can be introduced at the beginning of the fermentation or fed semi-continuously or continuously.
- the ketone can be added directly to the cultivation or advantageously after cultivation.
- the enzymes can be isolated from the organisms by the method described in the examples or used as a crude extract for the reaction. Recombinant production of the polypeptides according to the invention
- the invention furthermore relates to processes for the recombinant production of polypeptides according to the invention or functional, biologically active fragments thereof, wherein a polypeptide-producing microorganism is cultivated, where appropriate the expression of the polypeptides is induced and these are isolated from the culture.
- the polypeptides can thus also be produced on an industrial scale, if this is desired.
- the recombinant microorganism can be cultivated and fermented by known methods. Bacteria can be propagated, for example, in TB or LB medium and at a temperature of 20 to 40 ° C and a pH of 6 to 9. Suitable cultivation conditions are described in detail, for example, in T. Manitatis, E.F. Fritsch and J. Sambrook, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1989).
- the cells are then disrupted and the product is obtained from the lysate by known protein isolation methods.
- the cells can optionally be operated by high-frequency ultrasound, by high pressure, e.g. in a French pressure cell, by osmolysis, by the action of detergents, lytic enzymes or organic solvents, by homogenizers or by a combination of several of the processes listed.
- Purification of the polypeptides can be achieved with known chromatographic methods, such as molecular sieve chromatography (gel filtration), such as Q-Sepharose chromatography, ion exchange chromatography and hydrophobic chromatography, and with other customary methods such as ultrafiltration, crystallization, salting out, dialysis and native gel electrophoresis. Suitable methods are described, for example, in Cooper, F.G., Biochemical Working Methods, Walter de Gruyter Verlag, Berlin, New York or in Scopes, R., Protein Purification, Springer Verlag, New York, Heidelberg, Berlin.
- vector systems or oligonucleotides which extend the cDNA by certain nucleotide sequences and thus code for modified polypeptides or fusion proteins which serve, for example, for easier purification.
- suitable modifications are, for example, so-called “tags” which act as anchors, such as, for example, the modification known as hexa-histidine anchors or epitopes which can be recognized as antigens of antibodies (described, for example, in Harlow, E. and Lane, D., 1988, Antibodies: A Laboratory Manual, Cold Spring Harbor (NY) Press).
- anchors can be used to attach the proteins to a solid support, such as, for example, a polymer matrix, which can be filled, for example, in a chromatography column, or to a microtiter plate or to another support.
- a solid support such as, for example, a polymer matrix, which can be filled, for example, in a chromatography column, or to a microtiter plate or to another support.
- these anchors can also be used to recognize the proteins.
- customary markers such as fluorescent dyes, enzyme markers which form a detectable reaction product after reaction with a substrate, or radioactive markers, alone or in combination with the anchors, can be used to derivatize the proteins.
- the dehydrogenases can be used in the process according to the invention as free or immobilized enzyme.
- the process according to the invention is advantageously carried out at a temperature between 0 ° C. to 95 ° C., preferably between 10 ° C. to 85 ° C., particularly preferably between 15 ° C. to 75 ° C.
- the pH in the process according to the invention is advantageously kept between pH 4 and 12, preferably between pH 4.5 and 9, particularly preferably between pH 5 and 8.
- enantiomerically pure or chiral products such as 3-chloro-1- (thien-2-yl) - (S) - propan-1-ol, are to be understood as enantiomers which show an enantiomeric enrichment.
- Growing cells containing the nucleic acids, nucleic acid constructs or vectors according to the invention can be used for the method according to the invention.
- Dormant or disrupted cells can also be used.
- Disrupted cells are understood to mean, for example, cells which have been made permeable by treatment with, for example, solvents, or cells which have been broken up by means of enzyme treatment, by mechanical treatment (for example French press or ultrasound) or by some other method.
- the crude extracts thus obtained are advantageously suitable for the process according to the invention.
- Purified or purified enzymes can also be used for the process. Immobilized microorganisms or enzymes, which can advantageously be used in the reaction, are also suitable.
- the process according to the invention can be operated batchwise, semi-batchwise or continuously.
- the activity-colored gel of a dehydrogenase from Lu10288 isolated according to the invention Lane 1: Molecular weight standards from below: 47 kDa, 74 kDa, 121 kDa, 205 kDa; Lane 2: empty; Lane 3: homogenate supernatant; Lane 4: Value fraction Q-Sepharose; Lane 5: Value fraction Q-Sepharose (triple amount); Lane 6: Superdex value fraction; Lane 7: Mono-Q value fraction; Lane 8: Mono-P fraction;
- FIGS. 2A and 2B show a typical course of the reaction of various batches for the preparation of (S) -3-methylamino-1- (thien-2-yl) propan-1-ol I-S by reduction with a dehydrogenase from Lactobacillus brevis.
- FIG. 3A shows the result of the N-terminal sequencing of a blot band of dehydrogenase from Lu10288 isolated according to the invention
- FIG. 3B the sequencing data of various proteolytic fragments of a dehydrogenase from Lu10288 purified according to the invention; if a main sequence could be determined for several signals per sequencing step, this is shown underlined twice. Illegible positions are marked with "/"; for positions whose determination is subject to a certain degree of uncertainty, the amino acid residue is given in brackets. Two amino acids are indicated in one position if no clear preference can be given. "?" means an unknown or undetermined amino acid.
- the propanone from Example 1 was placed in a mixture of 400 ml of toluene and 200 g of methanol at 0 ° C. After the addition of 2 g of 30% aqueous sodium hydroxide solution, 21.4 g of sodium borohydride were added in portions over the course of 2.5 h. After stirring for 40 minutes at 0 ° C., the reaction mixture was mixed with 12.1 g of 40% aqueous methylamine solution. The mixture was stirred at 60 ° C. under autogenous pressure for 6 h. After cooling to room temperature, the solvent was removed, the residue was digested with toluene and filtered off. The filtrate was dried to give 175.8 g of the title compound as a light yellow solid.
- glucose dehydrogenase from commercial sources (eg Jülich Fine Chemicals Order No. 22.10 or 19.10) or from our own sources could be used, the latter being an E.coli XL10 Gold pUC19 clone which was the glucose dehydrogenase Gene from Bacillus subtilis (Genbank-Acc.No.M12276) contained (Lu11293).
- Each 150 ml medium was sterilized in two 1 liter Erlenmeyer flasks and completed with 5 ml sterile saline. After inoculation of an LB ampicillin agar plate, the precultures were incubated for 12 hours at 37 ° C. and 200 rpm and added to the fermentation medium. The fermentation was started at 37 ° C, 0.1 bar internal pressure, pH 7.0 (control with 20% phosphoric acid and 25% NaOH) with a gassing rate of 7.5 L / min and 300 rpm (control pO 2 between 20 and 50% with 10-20 L / min supply air and 500-1500 rpm).
- Example 4 Screening for dehydrogenases to reduce 3-chloro-1- (thien-2-yl) propan-1-one
- GC Hydrodex- ⁇ -6-TBDM, 25 m, 90 ° C 10min 5 ° C / min 180 ° C 10min, running time: 38 min, inlets: heater: 200 ° C, press: 106.8 kPa, total flow: 102 ml / min, split ratio: 125: 1, split flow: 99.8 ml / min, detector: 200 ° C or HPLC: Chiracel OD-H, 250 * 4.6mm (Daicel), 40 ° C, flow 1.0 ml / min, 0.0-1.0 min: 97.5% n-hexane + 2.5% isopropanol; Detection at 230 nm (alcohol) and 260 nm (ketone) at Rt 9.50 (3-chloro-1- (thien-2-yl) propan-1-one), Rt 16.60 min (R-3- Chloro-1- (thien-2-yl) propan-1-ol)
- Lactobacillus brevis strains Lu10288, 10290 and 10291 were isolated as follows.
- the pH of the solution was adjusted to 5.4.
- the solution was autoclaved 15 'at 121 ° C.
- KMB medium 50 ml of sterile glucose solution (5 g ad 50 ml H 2 0) and 40 ml ethanol were added with stirring and agar plates were poured.
- KMB medium 50 ml of sterile glucose solution (5 g ad 50 ml H 2 0) and 40 ml ethanol were added with stirring and agar plates were poured.
- the solution was autoclaved 15 'at 121 ° C.
- the glucose and the CaCO 3 (Riedel de Haen) were dissolved separately and autoclaved and mixed with the agar before pouring the plates.
- liquid KMB medium with 20 g / l fructose 24 h 37 ° C, 50 rpm
- the strains were characterized by determining the acid fermentation pattern (pH measurement and concentration determination of glucose, fructose, lactate, acetate, E- thanol by HPLC analysis of the culture supernatants).
- Heterofermentative strains with acetate and lactate formation were isolated and systematically characterized by analysis of the 16sRNA.
- Tables 1, 2 and 3 show exemplary strains or the sales and ee values.
- Example 5 Purification of the dehydrogenase from Lactobacillus brevis
- a Superdex 200 molecular sieve column (Pharmacia) with a diameter of 2.6 cm and a volume of 240 ml was equilibrated in 20 mM MES, 1 mM MgCl 2 , 1 tablet Complete per liter buffer (EDTA free), pH 7.1.
- the value fractions of the Q-Sepharose were combined (240 ml) and adjusted to 80% saturation by slowly adding 124 g of ammonium sulfate. The pH was kept at 7.1. The solution was stirred at 4 ° C. for 10 minutes and then centrifuged at 12,000 rpm for 20 minutes.
- the pellet obtained was resuspended in 5 ml of equilibration buffer and dialyzed for 1 hour at 4 degrees Celsius (10 kDa exclusion volume).
- the dialyzed solution was divided into two 9 ml portions and applied to the molecular sieve column at a flow of 4 ml per minute. 4 ml fractions were collected and tested. Fractions 48 to 56 were again active for both substrates.
- a preparative Mono-Q HR column (Pharmacia) with a volume of 20 ml was equilibrated in 20 mM MES, 1mM MgCl 2 , pH 7.1. 70 ml of the pooled superdex fractions were applied at a flow rate of 4 ml per minute. After washing the column, the column was developed with a linear gradient in 100 minutes after 100% 20 mM MES, 1 mM MgCl 2 , 0.5 M NaCl, pH 7.1. 4 ml fractions were collected. Active fractions (fractions 36 to 41) were pooled.
- the sample was diluted with the same volume of Novex "Native Tris-Glycine” sample buffer (Novex).
- the Tris-Glycine gels from Anamed (without SDS, 1 mm thick, 10 sample pockets) were installed in the running chamber.
- Invitrogen Tris-Glycine Native "running buffer (Invitrogen) (10x) used after dilution.
- the sample pockets were loaded and the gel started at 200 V and approx. 50 mA.
- the duration of the electrophoresis was approximately 1.5 hours.
- the running chamber was in ice water. After the gel was removed, it came into a glass dish and was washed in 50 mM MES, 8 mM MgCl 2 , pH 6.2 and incubated.
- the N-terminus of the dehydrogenase purified in this way was determined after SDS-PAGE and gel blotting by means of Edman sequencing (SEQ ID NO: 1).
- the fermentation was started at 28 ° C., 0.1 bar internal pressure, pH 6.0 with a gassing rate of 5 l / min and 500 rpm (regulation pO 2 > 20%) and ended after 26 h at an OD600 of 15.1 , homogenization:
- the harvested cells (378 g of bio-moist mass) were suspended in 1 l of 50 mM MES +1 mM MgCl 2 , pH 6.5 with 10 tablets Protease-Inhibitor Complete (without EDTA), from Röche (approx. 9 x conc.) And Opened twice with 1000 bar in a Microfluidizer Z04. After centrifugation (20 min / 10000 g) half of the clear supernatant (1.3 I homogenate) was purified as described below.
- fraction samples were diluted appropriately in 50 mM MES pH 6.0, 0.2 mM NaDH / NaDPH, 100 mM glucose, 50 ⁇ l / ml GDH and 10 mM 3-chloro-1- (thien-2-yl ) - Propan-1 -one tested for activity at 30 ° C.
- volume of 400 ml was equilibrated in 20 mM MES buffer, 1 mM MgCl 2 , pH 6.8. 650 ml of homogenate were mixed with 11 tablets Complete (protease inhibitor mixture) and applied to the Q-Sepharose column at an application rate of 7.5 ml / min. The detection was carried out at 280 nm. The mixture was then washed with 700 ml of the same buffer.
- Ammonium sulfate precipitation 41 ml of Q-Sepharose peak value fractions were ad 90% saturated with (NH 4 ) 2 SO 4 (pH 6.2), stirred for 30 min at 4 ° C. and then centrifuged for 10 min at 10,000 g. The pellet obtained was suspended in 10 ml of 20 mM MES, 1 mM MgCl 2 , 1 tablet / I Complete (without EDTA), from Röche, pH 6.2 and for 30 min against 20 mM MES, 1 mM MgCl 2 , 1 tablet / I Complete (without EDTA), Röche, pH 6.2, in a Slide-A-Lyzer, Pierce (10 kDa exclusion volume), dialyzed.
- a Superdex 200 molecular sieve column (Pharmacia) with a diameter of 2.6 cm and a volume of 240 ml was equilibrated in 20 mM MES, 1 mM MgCl 2 , 1 tablet Complete per liter buffer (EDTA free), pH 6.2.
- a Mono-Q HR5 / 5 column (from Pharmacia) with a volume of 1 ml was equilibrated in 20 mM MES, 1 mM MgCl 2 , pH 6.8. 10 ml of the combined value fractions of the Superdex column were applied at a flow rate of 1 ml per minute. After washing the column, the column was developed with a linear gradient in 100 minutes after 100% 20 mM MES, 1 mM MgCl 2 , 0.75 M NaCl, pH 6.8 and 10 minutes with 20 mM MES, 1 mM MgCl 2 , pH 6.8 rinsed. 1 ml of fractal ons collected (detection 226 nm). Active fractions (fractions 24 to 27) were pooled.
- Example 7 Preparation of (S) -3-methylamino-1- (thien-2-yl) propan-1-ol 1-S by reduction with a dehydrogenase from Lactobacillus brevis
- Lactobacillus brevis Lu10288 was grown and harvested as in Example 4.
- the resting cells (10-100 g / L biomass) were treated with 0.2-2 mM NAD (P) + , 1 to 100 g / L of the propanone from Example 1 (batch or fed-batch) and 18 g / L glucose added and incubated at 30 ° C for 2-8 h.
- the reaction was kept at pH 6.0-7.0 by titration with 0.5 M NaOH and followed by HPLC analysis.
- Figures 2A and B show typical courses according to approaches 1 and 2 respectively.
- the biomass was then removed by centrifugation and / or filtration.
- the NMR analysis of the MTBE extracts showed a 3-chloro-1- (thien-2-yl) propan-1-ol content of 60-70%.
- the contents of unreacted 3-chloro-1- (thien-2-yl) propan-1-one and of the by-product 1-thien-2-yl-propen-1-one were each below 10%.
- 1-Thien-2-yl-propen-1-ol could only be detected in traces.
- Example 8 Cloning of the dehydrogenase from Lactobacillus brevis Lu 10288 a) Chromosomal DNA preparation from LU10288 after previous protoplasting:
- Solutionl 0.41 M sucrose 0.01M MgSO 4 * 7H 2 O 5ml / l M12 medium 1: 2 10ml / M0% KH 2 PO 4 pH 6.7 2.5 mg / ml lysozyme (add shortly before use) Prepare solution 1 as follows:
- Proteinase Qiagen, 20mg / ml stock solution
- TE buffer 10mM Tris * CI pH8, 1mM EDTA pH 8
- Proteinase K (Qiagen Proteinase: 20 mg / ml, ie 50 ⁇ l) and incubate at 37 ° C overnight in the incubator.
- the mixture is filled into a dialysis tube. It is dialysed 3 times in each case for 1 hour at 4.degree. C. in 1.51 TE buffer. The last dialysis step is also possible overnight.
- the DNA was incubated for 1-2 hours in an Eppendorf shaker at 55-60 ° C at a gentle shaking frequency (400 rpm).
- sequence FWDGGYTAQ (cf. V8-RP Fr.7) presumably represents the C-terminus due to the termination. From this and from the N-terminal amino acid sequence (SEQ ID NO. 1) nucleic acid sequences were taken into account, taking into account the codon usage of Lactobacillus brevis derived (primers Mke338 and 339), which served as follows for cloning the dehydrogenase gene by PCR amplification on chromosomal DNA from Lu10288 (protocol see above).
- the PCR was carried out according to the Stratagene standard procedure with Pfu polymerase (Stratagene) and the following temperature program: 95 ° C. for 5 minutes; 30 cycles at 95 ° C for 45 sec, 52 ° C for 45 sec, and 72 ° C for 1 min 20 sec; 72 ° C for 10 min .; 10 ° C until use.
- the PCR product (0.8 kB) was isolated by agarose gel electrophoresis (1.2% E-gel, Invitrogen) and column chromatography (Mini-Elute, Qiagen) and then digested with Ndel / Hindlll and in appropriately digested pDHE19 .2 vector (a pJOE derivative, DE19848129) cloned.
- the ligation batches were transformed into E.coli XL1 Blue (Stratagene).
- the sequencing of corresponding clones resulted in the nucleic acid sequence shown in SEQ ID NO: 3, which corresponds to the amino acid sequence SEQ ID NO: 4, as an insert in the plasmid pDHE10288adh1 thus obtained. It contains all the peptides identified in Examples 5 and 8.
- SEQ ID NO: 3 nucleic acid sequence of the dehydrogenase of Lu10288 (as well as opposite strand) 1 ATGTCTAACC GTTTGGATGG AAAAGTAGCA ATCGTTACAG GTGGTACGTT TACAGATTGG CAAACCTACC TTTTCATCGT TAGCAATGTC CACCATGCAA 51 GGGTATCGGT TTAGCTATCG CCACGAAGTT CGTTGAAGAA GGGGCTAAGG CCCATAGCCA AATCGATAGC GGTGCTTCAA GCAACTTCTT CCCCGATTCC 101 TCATGATTAC CGGCCGGCAC AGCGATGTTG GTGAAAAAGC AGCTAAGAGT AGTACTAATG GCCGGCCGTG TCGCTACAAC CACTTTTTCG TCGATTCTCA 151 GTCGGCACTC CTGATCAGAT TCAATTTTTC CAACATGATT CTTCCGATGA CAGCCGTGAG GACTAGTCTA AGTTAAAAAGGCTACT 201 AGACGGCTGG ACG
- Example 9 Activity determination of the recombinant dehydrogenase from Lactobacillus brevis Lu 10288
- the plasmid pDHE10288adh1 was retransformed in E.coli TG10 pAgro4 pHSG575 (TG10: a RhaA ' derivative of E.coli TG 1 (Stratagene); pAgro4: Takeshita, S; Sato, M; Toba, M; Masahashi, W; Hashimoto- Gotoh, T (1987) Gene 61, 63-74; pHSG575: T. Tomoyasu et al (2001), Mol. Microbiol. 40 (2), 397-413).
- 100 ul cell suspension were 20 min in 900 ul 50mM MES pH6 with 50 ul / ml glucose-DH (example), 100mM glucose, 100mM NaCl, 1mM NADH, 1mM NADPH and with 10 mM 3-chloro-1- (thien-2-yl ) -propan-1-one incubated shaking.
- the batches were analyzed analogously to Example 4. On average 0.13 mM 3-chloro-1- (thien-2-yl) -propan-1-ol was formed, which corresponds to an activity of 6.6 U / L culture suspension.
- nucleic acid sequences (primers Mke366, 367 and 374) were derived from the peptides, which as follows are the cloning of the dehydrogenase gene by PCR amplification on chromosomal DNA from Lu8472 (genomic DNA kit with triple concentrated lyticase Solution, Qiagen, Hilden) served.
- the primers MKe366 and MKe367 were mixed 1: 1.
- the PCR was carried out according to the Strateumble standard specification with PfuTurbo polymerase (Stratagene) and the following temperature gradient program: 95 ° C. for 1 minute; 30 cycles at 95 ° C for 1 min., X ° C 1 for 45 sec, and 72 ° C for 2 min; 72 ° C for 10 min .; 10 ° C until use.
- the PCR product (-0.5 kB) was isolated by agarose gel electrophoresis (1.2% e-gel, Invitrogen) and column chromatography (GFX kit, Amersham Pharmacia) and then sequenced (sequencing primers: Mke 366 and Mke374 ).
- SEQ ID NO: 5 The amino acid sequence derived therefrom (SEQ ID NO: 6) shows an identity of 53% to the carbonyl reductase from Candida magnoliae (WO200140450). The peptide sequences determined after protein purification are included with minor deviations. Differences could
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK04765718.4T DK1670779T3 (da) | 2003-10-01 | 2004-09-30 | Fremgangsmåde til fremstilling af 3-methylamino-1-(thien-2-yl)-propan-1-ol |
US10/573,130 US7498448B2 (en) | 2003-10-01 | 2004-09-30 | Methods for the production of 3-methylamino-1-(thiene-2-yl)-propane-1-ol |
AT04765718T ATE489377T1 (de) | 2003-10-01 | 2004-09-30 | Verfahren zur herstellung von 3-methylamino-1- (thien-2-yl)-propan-1-ol |
EP04765718A EP1670779B1 (de) | 2003-10-01 | 2004-09-30 | Verfahren zur herstellung von 3-methylamino-1-(thien-2-yl)-propan-1-ol |
DE502004011932T DE502004011932D1 (de) | 2003-10-01 | 2004-09-30 | Verfahren zur herstellung von 3-methylamino-1-(thien-2-yl)-propan-1-ol |
CN2004800281086A CN1860110B (zh) | 2003-10-01 | 2004-09-30 | 产生3-甲基氨基-1-(噻吩-2-基)丙-1-醇的方法 |
SI200431560T SI1670779T1 (sl) | 2003-10-01 | 2004-09-30 | Postopki za pripravo 3-metilamino-1-(tien-2-il)-propan ola |
JP2006530058A JP2007533628A (ja) | 2003-10-01 | 2004-09-30 | 3−メチルアミノ−1−(チエン−2−イル)プロパン−1−オールの製造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10345772A DE10345772A1 (de) | 2003-10-01 | 2003-10-01 | Verfahren zur Herstellung von 3-Methylamino-1-(thien-2-yl)-propan-1-ol |
DE10345772.0 | 2003-10-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005033094A2 true WO2005033094A2 (de) | 2005-04-14 |
WO2005033094A3 WO2005033094A3 (de) | 2005-11-24 |
Family
ID=34353261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/010939 WO2005033094A2 (de) | 2003-10-01 | 2004-09-30 | Verfahren zur herstellung von 3-methylamino-1-(thien-2-yl)-propan-1-ol |
Country Status (11)
Country | Link |
---|---|
US (1) | US7498448B2 (de) |
EP (1) | EP1670779B1 (de) |
JP (2) | JP2007533628A (de) |
CN (1) | CN1860110B (de) |
AT (1) | ATE489377T1 (de) |
DE (2) | DE10345772A1 (de) |
DK (1) | DK1670779T3 (de) |
ES (1) | ES2357115T3 (de) |
PT (1) | PT1670779E (de) |
SI (1) | SI1670779T1 (de) |
WO (1) | WO2005033094A2 (de) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005108590A2 (de) * | 2004-05-05 | 2005-11-17 | Basf Aktiengesellschaft | Verfahren zur herstellung optisch aktiver alkohole aus alkanonen unter verwendung einer dehydrogenase aus azoarcus |
WO2006094945A2 (de) * | 2005-03-07 | 2006-09-14 | Basf Aktiengesellschaft | Verfahren zur herstellung optisch aktiver alkohole durch enzymatische reduktion |
WO2007033928A1 (de) * | 2005-09-19 | 2007-03-29 | Basf Se | Neue dehydrogenasen, deren derivate und ein verfahren zur herstellung von optisch aktiven alkanolen |
WO2007074070A1 (de) * | 2005-12-23 | 2007-07-05 | Basf Se | Enzymatische reduktion zur herstellung optisch aktiver alkohole |
WO2007074060A1 (de) * | 2005-12-23 | 2007-07-05 | Basf Se | Verfahren zur herstellung von optisch aktivem (1s)-3-chlor-1-(2-thienyl)-propan-1-ol |
WO2008004191A2 (en) | 2006-07-03 | 2008-01-10 | Ranbaxy Laboratories Limited | Process for the preparation of enantiomerically pure salts of n-methyl-3- ( 1-naphthaleneoxy) -3- (2-thienyl) propanamine |
EP2060559A1 (de) * | 2007-11-19 | 2009-05-20 | Cadila Pharmaceuticals Limited | Herstellungsverfahren für enantiomerenreine 3-Hydroxy-3-Arylpropylamine und ihrer optischen Stereoisomere |
WO2009029554A3 (en) * | 2007-08-24 | 2009-07-02 | Codexis Inc | Improved ketoreductase polypeptides for the stereoselective production of (r)-3-hydroxythiolane |
WO2010025238A2 (en) | 2008-08-27 | 2010-03-04 | Codexis, Inc. | Ketoreductase polypeptides for the production of a 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine |
EP2226386A1 (de) | 2009-03-05 | 2010-09-08 | IEP GmbH | Verfahren zur stereoselektiven enzymatischen Reduktion von Ketoverbindungen |
US7820421B2 (en) | 2007-02-08 | 2010-10-26 | Codexis, Inc. | Ketoreductases and uses thereof |
US7879585B2 (en) | 2006-10-02 | 2011-02-01 | Codexis, Inc. | Ketoreductase enzymes and uses thereof |
US7883879B2 (en) | 2007-10-01 | 2011-02-08 | Codexis, Inc. | Ketoreductase polypeptides for the production of azetidinone |
US8088610B2 (en) | 2007-09-28 | 2012-01-03 | Codexis, Inc. | Ketoreductases for the production of (S,E)-methyl 2-(3-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-hroxypropyl)benzoate |
US8273554B2 (en) | 2008-08-29 | 2012-09-25 | Codexis, Inc. | Ketoreductase polypeptides for the stereoselective production of (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one |
US8288141B2 (en) | 2008-08-27 | 2012-10-16 | Codexis, Inc. | Ketoreductase polypeptides for the production of 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine |
US8512973B2 (en) | 2007-09-13 | 2013-08-20 | Codexis, Inc. | Methods of using engineered ketoreductase polypeptides for the stereoselective reduction of acetophenones |
US8658400B2 (en) | 2008-12-17 | 2014-02-25 | Basf Se | Biocatalysts for manufacturing duloxetine alcohol |
US9040262B2 (en) | 2010-05-04 | 2015-05-26 | Codexis, Inc. | Biocatalysts for ezetimibe synthesis |
US9102959B2 (en) | 2009-08-19 | 2015-08-11 | Codexis, Inc. | Ketoreductase polypeptides for the preparation of phenylephrine |
US12049649B2 (en) | 2021-06-24 | 2024-07-30 | Codexis, Inc. | Ketoreductase polypeptides for the production of azetidinone |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9102963B2 (en) * | 2011-04-13 | 2015-08-11 | Codexis, Inc. | Biocatalytic process for preparing eslicarbazepine and analogs thereof |
CN107746861B (zh) * | 2017-11-20 | 2020-06-23 | 浙江工业大学 | 一种(r)-1-(2-三氟甲基苯基)乙醇的生物制备方法 |
CN117737149B (zh) * | 2024-02-20 | 2024-05-07 | 山东君泰药业有限公司 | 一种酶催化合成高纯度s-玻色因的方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003192681A (ja) * | 2001-12-27 | 2003-07-09 | Mitsubishi Rayon Co Ltd | (s)−3−クロロ−1−(2−チエニル)−1−プロパノール及び(s)−3−n−メチルアミノ−1−(2−チエニル)−1−プロパノールの製造方法 |
DE10248479A1 (de) * | 2002-10-17 | 2004-05-06 | Consortium für elektrochemische Industrie GmbH | Verfahren zur Herstellung von Thienyl-substituierten sekundären Aminoalkoholen |
DE10248480A1 (de) * | 2002-10-17 | 2004-05-06 | Consortium für elektrochemische Industrie GmbH | Verfahren zur Herstellung von Thienyl-substituierten sekundären Aminoalkoholen |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3803173A (en) * | 1971-04-26 | 1974-04-09 | Degussa | 3-(3-(1-(4-hydroxyphenyl)-1-hydroxypropyl-(2)-amino)-propionyl)-thiophene |
KR880007433A (ko) | 1986-12-22 | 1988-08-27 | 메리 앤 터커 | 3-아릴옥시-3-치환된 프로판아민 |
FI912280A (fi) | 1990-05-17 | 1991-11-18 | Lilly Co Eli | Kiral syntes av 1-aryl-3-aminopropan-1 -oler. |
US5362886A (en) * | 1993-10-12 | 1994-11-08 | Eli Lilly And Company | Asymmetric synthesis |
DE19857302C2 (de) * | 1998-12-14 | 2000-10-26 | Forschungszentrum Juelich Gmbh | Verfahren zur enantioselektiven Reduktion von 3,5-Dioxocarbonsäuren, deren Salze und Ester |
EP1194582A1 (de) * | 1999-07-09 | 2002-04-10 | Forschungszentrum Jülich Gmbh | Verfahren zur reduktion von keto-carbonsäuren und deren estern |
DE19931847A1 (de) * | 1999-07-09 | 2001-01-11 | Basf Ag | Immobilisierte Lipase |
CZ20012792A3 (cs) * | 1999-12-03 | 2002-03-13 | Kaneka Corporation | Polypeptid, polynukleotid kódující polypeptid, expresní vektor, transformant a způsob přípravy |
DE10019380A1 (de) | 2000-04-19 | 2001-10-25 | Basf Ag | Verfahren zur Herstellung von kovalent gebundenen biologisch aktiven Stoffen an Polyurethanschaumstoffen sowie Verwendung der geträgerten Polyurethanschaumstoffe für chirale Synthesen |
JP4818507B2 (ja) * | 2000-11-21 | 2011-11-16 | 三菱レイヨン株式会社 | 光学活性3−キヌクリジノールの製造法 |
JP2002165393A (ja) * | 2000-11-27 | 2002-06-07 | Toshiba Tec Corp | ブラシレスモータ |
JP4913296B2 (ja) * | 2001-09-21 | 2012-04-11 | 三菱レイヨン株式会社 | 光学活性アルコール及びその製造方法 |
US7148055B2 (en) * | 2001-10-05 | 2006-12-12 | Kaneka Corporation | Process for production of optically active 3-hydroxypentanenitrile |
JP2003199595A (ja) * | 2001-10-24 | 2003-07-15 | Daicel Chem Ind Ltd | 光学活性マンデル酸誘導体の製造方法 |
-
2003
- 2003-10-01 DE DE10345772A patent/DE10345772A1/de not_active Withdrawn
-
2004
- 2004-09-30 SI SI200431560T patent/SI1670779T1/sl unknown
- 2004-09-30 JP JP2006530058A patent/JP2007533628A/ja active Pending
- 2004-09-30 AT AT04765718T patent/ATE489377T1/de active
- 2004-09-30 ES ES04765718T patent/ES2357115T3/es active Active
- 2004-09-30 CN CN2004800281086A patent/CN1860110B/zh not_active Expired - Fee Related
- 2004-09-30 PT PT04765718T patent/PT1670779E/pt unknown
- 2004-09-30 WO PCT/EP2004/010939 patent/WO2005033094A2/de active Search and Examination
- 2004-09-30 DE DE502004011932T patent/DE502004011932D1/de active Active
- 2004-09-30 US US10/573,130 patent/US7498448B2/en not_active Expired - Fee Related
- 2004-09-30 DK DK04765718.4T patent/DK1670779T3/da active
- 2004-09-30 EP EP04765718A patent/EP1670779B1/de not_active Not-in-force
-
2011
- 2011-01-14 JP JP2011005361A patent/JP2011142908A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003192681A (ja) * | 2001-12-27 | 2003-07-09 | Mitsubishi Rayon Co Ltd | (s)−3−クロロ−1−(2−チエニル)−1−プロパノール及び(s)−3−n−メチルアミノ−1−(2−チエニル)−1−プロパノールの製造方法 |
DE10248479A1 (de) * | 2002-10-17 | 2004-05-06 | Consortium für elektrochemische Industrie GmbH | Verfahren zur Herstellung von Thienyl-substituierten sekundären Aminoalkoholen |
DE10248480A1 (de) * | 2002-10-17 | 2004-05-06 | Consortium für elektrochemische Industrie GmbH | Verfahren zur Herstellung von Thienyl-substituierten sekundären Aminoalkoholen |
Non-Patent Citations (9)
Title |
---|
ANGEWANDTE CHEMIE (INTERNATIONAL ED. IN ENGLISH), Bd. 43, Nr. 7, 6. Februar 2004 (2004-02-06), Seiten 788-824, XP002339848 * |
DATABASE EMBL [Online] 14. Februar 2003 (2003-02-14), "Lactobacillus brevis radh gene for R-specific alcohol dehydrogenase" XP002339858 Database accession no. AJ544275 & DATABASE UniProt 1. Juni 2003 (2003-06-01), "R-specific alcohol dehydrogenase" XP002339859 Database accession no. Q84EX5 * |
DATABASE EMBL [Online] 9. August 2001 (2001-08-09), "Sequence 7 from patent US 6225099" XP002339860 Database accession no. AR148418 & DATABASE USPTO PROTEINS [Online] 8. August 2001 (2001-08-08), "Sequence 8 from patent US 6225099" XP002339861 Database accession no. AAE68828 * |
DATABASE GENESEQ [Online] 31. August 2001 (2001-08-31), "DNA encoding Candida magnoliae carbonyl reductase" XP002339862 Database accession no. AAH27641 & DATABASE GENESEQ [Online] 31. August 2001 (2001-08-31), "Candida magnoliae carbonyl reductase" XP002339863 Database accession no. AAB97187 * |
HUMMEL W: "NEW ALCOHOL DEHYDROGENASES FOR THE SYNTHESIS OF CHIRAL COMPOUNDS" 1997, ADVANCES IN BIOCHEMICAL ENGINEERING, BIOTECHNOLOGY, SPRINGER, BERLIN, DE, PAGE(S) 145-184 , XP000677754 ISSN: 0724-6145 das ganze Dokument * |
KAMAL A ET AL: "Chemoenzymatic synthesis of duloxetine and its enantiomer: lipase-catalyzed resolution of 3-hydroxy-3-(2-thienyl) propanenitrile" TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, Bd. 44, Nr. 25, 16. Juni 2003 (2003-06-16), Seiten 4783-4787, XP004426893 ISSN: 0040-4039 in der Anmeldung erwähnt * |
LIU H ET AL: "CHEMO-ENZYMATIC SYNTHESIS OF THE ANTIDEPRESSANT DULOXETINE AND ITS ENANTIOMER" CHIRALITY, WILEY-LISS, NEW YORK, US, Bd. 12, Nr. 1, 2000, Seiten 26-29, XP009000316 ISSN: 0899-0042 in der Anmeldung erwähnt * |
PATENT ABSTRACTS OF JAPAN Bd. 2003, Nr. 11, 5. November 2003 (2003-11-05) & JP 2003 192681 A (MITSUBISHI RAYON CO LTD), 9. Juli 2003 (2003-07-09) * |
WHEELER W J ET AL: "AN ASYMMETRIC SYNTHESIS OF DULOXETINE HYDROCHLORIDE, A MIXED UPTAKE INHIBITOR FOR SEROTONIN AND NOREPHINEPHRINE, AND ITS C-14 LABELED ISOTOPOMERS" JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, SUSSEX, GB, Bd. 36, Nr. 3, 1995, Seiten 213-224, XP009019756 ISSN: 0362-4803 in der Anmeldung erwähnt * |
Cited By (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005108590A3 (de) * | 2004-05-05 | 2006-04-06 | Basf Ag | Verfahren zur herstellung optisch aktiver alkohole aus alkanonen unter verwendung einer dehydrogenase aus azoarcus |
US7785847B2 (en) | 2004-05-05 | 2010-08-31 | Basf Se | Method for producing optically active alcohols from alkanones using a dehydrogenase of azoarcus |
WO2005108590A2 (de) * | 2004-05-05 | 2005-11-17 | Basf Aktiengesellschaft | Verfahren zur herstellung optisch aktiver alkohole aus alkanonen unter verwendung einer dehydrogenase aus azoarcus |
WO2006094945A2 (de) * | 2005-03-07 | 2006-09-14 | Basf Aktiengesellschaft | Verfahren zur herstellung optisch aktiver alkohole durch enzymatische reduktion |
WO2006094945A3 (de) * | 2005-03-07 | 2007-03-15 | Basf Ag | Verfahren zur herstellung optisch aktiver alkohole durch enzymatische reduktion |
JP2009508479A (ja) * | 2005-09-19 | 2009-03-05 | ビーエーエスエフ ソシエタス・ヨーロピア | 新規デヒドロゲナーゼ、その誘導体および光学活性アルカノールの製造方法 |
WO2007033928A1 (de) * | 2005-09-19 | 2007-03-29 | Basf Se | Neue dehydrogenasen, deren derivate und ein verfahren zur herstellung von optisch aktiven alkanolen |
US8455223B2 (en) | 2005-09-19 | 2013-06-04 | Basf Se | Dehydrogenases, the derivatives thereof, and method for the production of optically active alkanols |
JP2009520482A (ja) * | 2005-12-23 | 2009-05-28 | ビーエーエスエフ ソシエタス・ヨーロピア | 光学活性(1s)−3−クロロ−1−(2−チエニル)−プロパン−1−オールの製造方法 |
US7790436B2 (en) | 2005-12-23 | 2010-09-07 | Basf Se | Method for production of (1S)-3-chloro-1-(2-thienyl)-propan-1-ol using alcohol dehydrogenase from thermoanaerobacter |
CN101316932B (zh) * | 2005-12-23 | 2012-02-22 | 巴斯夫欧洲公司 | 制备旋光的(1s)-3-氯-1-(2-噻酚基)-丙-1-醇的方法 |
JP2009520483A (ja) * | 2005-12-23 | 2009-05-28 | ビーエーエスエフ ソシエタス・ヨーロピア | 光学活性アルコールを製造するための酵素的還元 |
US7888080B2 (en) | 2005-12-23 | 2011-02-15 | Basf Se | Enzymatic reduction for producing optically active alcohols |
WO2007074070A1 (de) * | 2005-12-23 | 2007-07-05 | Basf Se | Enzymatische reduktion zur herstellung optisch aktiver alkohole |
WO2007074060A1 (de) * | 2005-12-23 | 2007-07-05 | Basf Se | Verfahren zur herstellung von optisch aktivem (1s)-3-chlor-1-(2-thienyl)-propan-1-ol |
WO2008004191A2 (en) | 2006-07-03 | 2008-01-10 | Ranbaxy Laboratories Limited | Process for the preparation of enantiomerically pure salts of n-methyl-3- ( 1-naphthaleneoxy) -3- (2-thienyl) propanamine |
US8617864B2 (en) | 2006-10-02 | 2013-12-31 | Codexis, Inc. | Polynucleotides encoding ketoreductases for producing stereoisomerically pure statins and synthetic intermediates therefor |
US7879585B2 (en) | 2006-10-02 | 2011-02-01 | Codexis, Inc. | Ketoreductase enzymes and uses thereof |
US8273547B2 (en) | 2006-10-02 | 2012-09-25 | Codexis, Inc. | Engineered ketoreductases and methods for producing stereoisomerically pure statins |
US8415127B2 (en) | 2007-02-08 | 2013-04-09 | Codexis, Inc. | Ketoreductases and uses thereof |
US7820421B2 (en) | 2007-02-08 | 2010-10-26 | Codexis, Inc. | Ketoreductases and uses thereof |
US8980605B2 (en) | 2007-02-08 | 2015-03-17 | Codexis, Inc. | Ketoreductases and uses thereof |
US8071347B2 (en) | 2007-02-08 | 2011-12-06 | Codexis, Inc. | Ketoreductases and uses thereof |
US8962285B2 (en) | 2007-08-24 | 2015-02-24 | Codexis, Inc. | Ketoreductase polypeptides for the production of (R)-3-hydroxythiolane |
US10851397B2 (en) | 2007-08-24 | 2020-12-01 | Codexis, Inc. | Ketoreductase polypeptides for the production of (R)-3-hydroxythiolane |
US7977078B2 (en) | 2007-08-24 | 2011-07-12 | Codexis, Inc. | Ketoreductase polypeptides for the production of (R)-3-hydroxythiolane |
US8227229B2 (en) | 2007-08-24 | 2012-07-24 | Codexis, Inc. | Ketoreductase polypeptides for the production of (R)-3-hydroxythiolane |
WO2009029554A3 (en) * | 2007-08-24 | 2009-07-02 | Codexis Inc | Improved ketoreductase polypeptides for the stereoselective production of (r)-3-hydroxythiolane |
US11965194B2 (en) | 2007-08-24 | 2024-04-23 | Codexis, Inc. | Ketoreductase polypeptides for the production of (R)-3-hydroxythiolane |
US9394552B2 (en) | 2007-08-24 | 2016-07-19 | Codexis, Inc. | Ketoreductase polypeptides for the production of (R)-3-hydroxythiolane |
US10385371B2 (en) | 2007-08-24 | 2019-08-20 | Codexis, Inc. | Ketoreductase polypeptides for the production of (R)-3-hydroxythiolane |
US11427841B2 (en) | 2007-08-24 | 2022-08-30 | Codexis, Inc. | Ketoreductase polypeptides for the production of (R)-3-hydroxythiolane |
US9932615B2 (en) | 2007-08-24 | 2018-04-03 | Codexis, Inc. | Ketoreductase polypeptides for the production of (R)-3-hydroxythiolane |
CN101784669B (zh) * | 2007-08-24 | 2015-02-18 | 科德克希思公司 | 用于(r)-3-羟基四氢噻吩的立体选择性制备的改善的酮还原酶多肽 |
US10927351B2 (en) | 2007-09-13 | 2021-02-23 | Codexis, Inc. | Ketoreductase polypeptides for the reduction of acetophenones |
US9873863B2 (en) | 2007-09-13 | 2018-01-23 | Codexis, Inc. | Polynucleotides encoding ketoreductase polypeptides for reduction of acetophenones |
US8512973B2 (en) | 2007-09-13 | 2013-08-20 | Codexis, Inc. | Methods of using engineered ketoreductase polypeptides for the stereoselective reduction of acetophenones |
US9951318B1 (en) | 2007-09-13 | 2018-04-24 | Codexis, Inc. | Ketoreductase polypeptides for the reduction of acetophenones |
US10100288B2 (en) | 2007-09-13 | 2018-10-16 | Codexis, Inc. | Ketoreductase polypeptides for the reduction of acetophenones |
US11479756B2 (en) | 2007-09-13 | 2022-10-25 | Codexis, Inc. | Ketoreductase polypeptides for the reduction of acetophenones |
US10227572B2 (en) | 2007-09-13 | 2019-03-12 | Codexis, Inc. | Ketoreductase polypeptides for the reduction of acetophenones |
US8748143B2 (en) | 2007-09-13 | 2014-06-10 | Codexis, Inc. | Ketoreductase polypeptides for the reduction of acetophenones |
US8852909B2 (en) | 2007-09-13 | 2014-10-07 | Codexis, Inc. | Ketoreductase polypeptides for the reduction of acetophenones |
US9528131B2 (en) | 2007-09-13 | 2016-12-27 | Codexis, Inc. | Methods of using ketoreductase polypeptides for reduction of acetophenones |
US8088610B2 (en) | 2007-09-28 | 2012-01-03 | Codexis, Inc. | Ketoreductases for the production of (S,E)-methyl 2-(3-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-hroxypropyl)benzoate |
US8617853B2 (en) | 2007-09-28 | 2013-12-31 | Codexis, Inc. | Ketoreductase polypeptides for the production of (S,E)-methyl 2-(3-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-hydroxypropyl)benzoate |
US10597641B2 (en) | 2007-10-01 | 2020-03-24 | Codexis, Inc. | Ketoreductase polypeptides for the production of azetidinone |
US9580694B2 (en) | 2007-10-01 | 2017-02-28 | Codexis, Inc. | Ketoreductase polypeptides for the production of azetidinone |
US8980606B2 (en) | 2007-10-01 | 2015-03-17 | Codexis, Inc. | Ketoreductase polypeptides for the production of azetidinone |
US9133442B2 (en) | 2007-10-01 | 2015-09-15 | Codexis, Inc. | Ketoreductase polypeptides for the production of azetidinone |
US10329540B2 (en) | 2007-10-01 | 2019-06-25 | Codexis, Inc. | Ketoreductase polypeptides for the production of azetidinone |
US8470572B2 (en) | 2007-10-01 | 2013-06-25 | Codexis, Inc. | Ketoreductase polypeptides for the production of azetidinone |
US9382519B2 (en) | 2007-10-01 | 2016-07-05 | Codexis, Inc. | Ketoreductase polypeptides for the production of azetidinone |
US11078466B2 (en) | 2007-10-01 | 2021-08-03 | Codexis, Inc. | Ketoreductase polypeptides for the production of azetidinone |
US7883879B2 (en) | 2007-10-01 | 2011-02-08 | Codexis, Inc. | Ketoreductase polypeptides for the production of azetidinone |
US9719071B2 (en) | 2007-10-01 | 2017-08-01 | Codexis, Inc. | Ketoreductase polypeptides for the production of azetidinone |
US9476034B2 (en) | 2007-10-01 | 2016-10-25 | Codexis, Inc. | Ketoreductase polypeptides for the production of azetidinone |
US8257952B2 (en) | 2007-10-01 | 2012-09-04 | Codexis, Inc. | Ketoreductase polypeptides for the production of azetidinone |
EP2060559A1 (de) * | 2007-11-19 | 2009-05-20 | Cadila Pharmaceuticals Limited | Herstellungsverfahren für enantiomerenreine 3-Hydroxy-3-Arylpropylamine und ihrer optischen Stereoisomere |
US8673607B2 (en) | 2008-08-27 | 2014-03-18 | Codexis, Inc. | Ketoreductase polypeptides for the production of a 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine |
EP2329013B1 (de) * | 2008-08-27 | 2015-10-28 | Codexis, Inc. | Ketoreduktasepolypeptide zur herstellung von einem 3-aryl-3-hydroxypropanamin aus einem 3-aryl-3-ketopropanamin |
US8288141B2 (en) | 2008-08-27 | 2012-10-16 | Codexis, Inc. | Ketoreductase polypeptides for the production of 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine |
US8426178B2 (en) | 2008-08-27 | 2013-04-23 | Codexis, Inc. | Ketoreductase polypeptides for the production of a 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine |
WO2010025238A2 (en) | 2008-08-27 | 2010-03-04 | Codexis, Inc. | Ketoreductase polypeptides for the production of a 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine |
US10047348B2 (en) | 2008-08-29 | 2018-08-14 | Codexis, Inc. | Ketoreductase polypeptides |
US9139820B2 (en) | 2008-08-29 | 2015-09-22 | Codexis, Inc. | Ketoreductase polypeptides |
US8273554B2 (en) | 2008-08-29 | 2012-09-25 | Codexis, Inc. | Ketoreductase polypeptides for the stereoselective production of (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one |
US9422530B2 (en) | 2008-08-29 | 2016-08-23 | Codexis, Inc. | Ketoreductase polypeptides |
US8415126B2 (en) | 2008-08-29 | 2013-04-09 | Codexis, Inc. | Polynucleotides encoding recombinant ketoreductase polypeptides |
US10246687B2 (en) | 2008-08-29 | 2019-04-02 | Codexis, Inc. | Ketoreductase polypeptides |
US8956840B2 (en) | 2008-08-29 | 2015-02-17 | Codexis, Inc. | Engineered ketoreductase polypeptides |
US10988739B2 (en) | 2008-08-29 | 2021-04-27 | Codexis, Inc. | Ketoreductase polypeptides |
US10544401B2 (en) | 2008-08-29 | 2020-01-28 | Codexis, Inc. | Ketoreductase polypeptides |
US9796964B2 (en) | 2008-08-29 | 2017-10-24 | Codexis, Inc. | Ketoreductase polypeptides |
US8658400B2 (en) | 2008-12-17 | 2014-02-25 | Basf Se | Biocatalysts for manufacturing duloxetine alcohol |
EP2226386A1 (de) | 2009-03-05 | 2010-09-08 | IEP GmbH | Verfahren zur stereoselektiven enzymatischen Reduktion von Ketoverbindungen |
WO2010100195A1 (de) | 2009-03-05 | 2010-09-10 | Iep Gmbh | Verfahren zur stereoselektiven enzymatischen reduktion von ketoverbindungen |
US10590396B2 (en) | 2009-08-19 | 2020-03-17 | Codexis, Inc. | Ketoreductase polypeptides for the preparation of phenylephrine |
US9834758B2 (en) | 2009-08-19 | 2017-12-05 | Codexis, Inc. | Ketoreductase polypeptides for the preparation of phenylephrine |
US12031159B2 (en) | 2009-08-19 | 2024-07-09 | Codexis, Inc. | Ketoreductase polypeptides for the preparation of phenylephrine |
US10870835B2 (en) | 2009-08-19 | 2020-12-22 | Codexis, Inc. | Ketoreductase polypeptides for the preparation of phenylephrine |
US9102959B2 (en) | 2009-08-19 | 2015-08-11 | Codexis, Inc. | Ketoreductase polypeptides for the preparation of phenylephrine |
US10358631B2 (en) | 2009-08-19 | 2019-07-23 | Codexis, Inc. | Ketoreductase polypeptides for the preparation of phenylephrine |
US11345898B2 (en) | 2009-08-19 | 2022-05-31 | Codexis, Inc. | Ketoreductase polypeptides for the preparation of phenylephrine |
US9040262B2 (en) | 2010-05-04 | 2015-05-26 | Codexis, Inc. | Biocatalysts for ezetimibe synthesis |
US10995320B2 (en) | 2010-05-04 | 2021-05-04 | Codexis, Inc. | Biocatalysts for Ezetimibe synthesis |
US10544400B2 (en) | 2010-05-04 | 2020-01-28 | Codexis, Inc. | Biocatalysts for ezetimibe synthesis |
US10053673B2 (en) | 2010-05-04 | 2018-08-21 | Codexis, Inc. | Biocatalysts for Ezetimibe synthesis |
US9644189B2 (en) | 2010-05-04 | 2017-05-09 | Codexis, Inc. | Biocatalysts for ezetimibe synthesis |
US9388391B2 (en) | 2010-05-04 | 2016-07-12 | Codexis, Inc. | Biocatalysts for Ezetimibe synthesis |
US12049649B2 (en) | 2021-06-24 | 2024-07-30 | Codexis, Inc. | Ketoreductase polypeptides for the production of azetidinone |
Also Published As
Publication number | Publication date |
---|---|
EP1670779A2 (de) | 2006-06-21 |
US7498448B2 (en) | 2009-03-03 |
DK1670779T3 (da) | 2011-02-28 |
DE10345772A1 (de) | 2005-04-21 |
JP2007533628A (ja) | 2007-11-22 |
US20070083055A1 (en) | 2007-04-12 |
WO2005033094A3 (de) | 2005-11-24 |
DE502004011932D1 (de) | 2011-01-05 |
ATE489377T1 (de) | 2010-12-15 |
PT1670779E (pt) | 2010-12-16 |
EP1670779B1 (de) | 2010-11-24 |
JP2011142908A (ja) | 2011-07-28 |
CN1860110A (zh) | 2006-11-08 |
CN1860110B (zh) | 2012-03-21 |
ES2357115T3 (es) | 2011-04-18 |
SI1670779T1 (sl) | 2011-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1670779B1 (de) | Verfahren zur herstellung von 3-methylamino-1-(thien-2-yl)-propan-1-ol | |
EP1745133B1 (de) | Verfahren zur herstellung optisch aktiver alkohole aus alkanonen unter verwendung einer dehydrogenase aus azoarcus | |
WO2006094945A2 (de) | Verfahren zur herstellung optisch aktiver alkohole durch enzymatische reduktion | |
EP2334801A2 (de) | Verfahren zur herstellung von l-phenylephrin unter verwendung einer alkohol dehydrogenase aus aromatoleum aromaticum ebn1 (azoarcus sp. ebn1) | |
EP2171074B1 (de) | Verfahren zur Herstellung optisch aktiver Alkohole unter Verwendung einer Dehydrogenase aus Azoarcus sp. EbN1 | |
EP1929001A1 (de) | Neue dehydrogenasen, deren derivate und ein verfahren zur herstellung von optisch aktiven alkanolen | |
EP1969132B1 (de) | Enzymatische reduktion zur herstellung optisch aktiver alkohole | |
EP1613745B1 (de) | L-carnitin dehydrogenasen, deren derivate und ein verfahren zur herstellung von substituierten (s)-alkanolen | |
EP1815002B1 (de) | Verfahren zur herstellung von (s)-butan-2-ol | |
WO2014086702A2 (de) | Enzymatische reduktion von hydroxymethylfurfuralen | |
WO2007071578A2 (de) | Verfahren zur herstellung von 5 -norbornen-2-carbonsäure aus 5-norbornen-2-carbonitril unter verwendung einer arylacetonitrilase | |
WO2012069434A1 (de) | Verfahren zur herstellung n-heterozyklischer optisch aktiver alkohole | |
WO2010079068A1 (de) | Verbesserte biokatalysatoren zur herstellung von duloxetinalkohol | |
Shahzad et al. | Chemoenzymatic Approaches towards (S)-Duloxetine | |
Danish Shahzad et al. | Chemoenzymatic Approaches towards (S)-Duloxetine | |
Kamal et al. | Lipase mediated resolution of γ-azidoalcohols in aqueous and organic media: Synthesis of (R)-and (S)-fluoxetine and duloxetine | |
JP2006509518A (ja) | 2−ヒドロキシ−3−(2−チエニル)プロパンニトリルのr及びs鏡像体の立体選択的製造のための化学酵素的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480028108.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004765718 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006530058 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007083055 Country of ref document: US Ref document number: 10573130 Country of ref document: US |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWP | Wipo information: published in national office |
Ref document number: 2004765718 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10573130 Country of ref document: US |